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Pancreatic cancer is an almost universally lethal disease, with five-year survival rates 
approaching 6%.  Its dismal prognosis is a consequence of several factors, including a 
lack of early detection methods, the inherent aggressive nature of this disease, and   
largely ineffective therapeutic regimens. Moreover, an overwhelming majority of patients 
are diagnosed at an advanced stage after their tumor has already metastasized.  Decades 
of research have shed light onto the genes and signaling pathways that drive pancreatic 
carcinogenesis and progression. The transforming growth factor-beta (TGFβ) signaling 
pathway is often perturbed in pancreatic cancer, with alterations to the key transcription 
factor SMAD4 being observed in over half of all tumors. Paradoxically, TGFβ exerts 
both tumor suppressive and tumor-promoting influences. TGFβ suppresses tumor 
formation by regulating cell cycle progression and promoting apoptosis. However, it can 
also promote tumor progression by both cell autonomous and non-autonomous signaling 
mechanisms, namely, by promoting epithelial-mesenchymal transition, stromal 
deposition, and immune evasion.  In pancreatic cancer, SMAD4 loss portends a worse 
prognosis and is correlated with widely metastatic disease. The goal of this thesis was to 
further understand the relationship between TGFβ signaling and metastatic efficiency in 
pancreatic cancer, with a particular interest on how TGFβ signaling in the tumor 
epithelium influences the tumor microenvironment.  Using a novel conditional mouse 
model of pancreatic cancer, we show that reduced TGFβ signaling in invasive PDA 
results in the oligometastatic phenotype whereas oncogenic TGFβ signaling promotes 
widely metastatic disease. Additionally, inactivation of either TGFβR2 or SMAD4 in 
 iii 
pancreatic cancer cells alters the immune response in invasive disease by mediating the 
accumulation of regulatory immune cell subsets. It will be important to further 
investigate how TGFβ signaling facilitates the recruitment and polarization of these cells 
into tumors and the extent to which it influences their function in order to fully appreciate 
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Chapter 1 : Pancreatic Adenocarcinoma Background 
Portions of this chapter have been published in a review and are reprinted here with 
permission from Wiley Periodicals, Inc. 
 
Macgregor-Das AM and Iacobuzio-Donahue CA. 2013. Molecular pathways in 


















Every year in the United States, approximately 44,000 people are diagnosed with 
pancreatic adenocarcinoma (PDA).  It is among the most lethal of all cancers, with nearly 
38,000 deaths per year and five-year survival rates of 6%. To date, pancreatic cancer 
remains the 4
th
 leading cause of cancer deaths among both men and women (1).  
A number of genetic studies have proven instrumental in elucidating the key 
genes, and more recently molecular pathways, that drive the formation and progression of 
pancreatic cancer. Early studies identified several genes that are frequently altered in 
pancreatic cancers (2). Subsequent analysis of the precursor lesions giving rise to 
pancreatic cancer indicated the temporal accumulation of these genetic alterations during 
pancreatic carcinogenesis (3). Most recently, next generation sequencing technologies 
have revealed the genetic landscape of neoplasms that arise from preinvasive neoplasms 
of the pancreas. Such surveys are helping to shape the development of new, personalized 
approaches to clinical management and therapy for pancreatic cancer patients.  
Pancreatic Carcinogenesis 
Precursors to Pancreatic Cancer. Three precursors to pancreatic cancer have 
been described (4; 5).  The vast majority of pancreatic cancers develop from microscopic 
precursors called pancreatic intraepithelial neoplasia (PanIN), that originate in small 
terminal (<5 mm) pancreatic ducts (4) (Figure 1.1).  PanINs are further classifiable based 
on their degree of morphologic atypia. In PanIN-1 lesions transformation of the normal 
ductal epithelium into tall columnar cells with intracellular mucin is seen, whereas 
PanIN-2 lesions are notable for the development of cytologic atypia and nuclear 
crowding. PanIN-3 lesions are characterized by extensive nuclear crowding and nuclear 
atypia, pseudopapillary growth, mitotic figures and intraluminal necrosis (4; 6).  
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Figure 1-1: Morphologic Progression Model of Pancreatic Intraepithelial Neoplasia 
Shown from left to right are histological examples of a normal pancreatic duct, pancreatic 
intraepithelial neoplasia (PanIN), and pancreatic cancer. Normal ducts are characterized by a low 
cuboidal epithelium surrounded by a periductal fibrotic cuff. PanIN‐1 lesions are differentiated 
from normal ductal epithelium by the presence of mucinous hyperplasia of the ductal cells 
(arrows) but without cytological atypia. PanIN‐2 lesions are notable for the presence of nuclear 
enlargement, atypia, crowding and papillary infoldings of the epithelium. PanIN‐3 lesions, 
synonymous to high‐grade dysplasia/carcinoma in situ, show a complete loss of cell polarity 
(arrows) and marked cytological atypia in association with frequent mitotic figures and 
pseudopapillary growth of the neoplastic epithelium. PanIN‐3 lesions may progress to invasive 
cancer that is characterized by poorly formed neoplastic glands with an infiltrative growth pattern 
admixed with abundant desmoplastic stroma. 
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By contrast, intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic 
neoplasms (MCNs) are macroscopically visible cystic neoplasms.  IPMNs arise in the 
mucin-producing main pancreatic duct or one of its branches (Figure 1.2A; 1.2B) where 
they distend the duct system by intraductal growth of the neoplasm and by copious mucin 
production.  MCNs are typically intraparenchymal and do not communicate with the 
pancreatic duct system (Figure 1.2C; 1.2D).  Histologically, MCNs are characterized by a 
mucinous epithelial lining in association with an underlying ovarian-like stroma (Figure 
1.2D).  A detailed discussion of the morphologic features of dysplasia in cystic 
precursors is beyond the scope of this review, but both IPMNs and MCNs also show a 
range of morphologic features ranging from low grade, to moderate, to high grade 
dysplasia (5).  Ultimately, pancreatic cancer may arise from any of these above precursor 
lesions yet cancers arising in association with PanINs are much more common (7).  
The Genetic Progression Model. The genetic events that accumulate during 
carcinogenesis have been best described for PanINs (Figure 1.3). Genetic events detected 
in PanIN-1 lesions include telomere shortening and activating mutations in KRAS (8; 9). 
PanIN-2 lesions exhibit CDKN2A loss while PanIN-3 lesions demonstrate genetic 
inactivation in TP53, SMAD4 and BRCA2 (8). Of course, exceptions to these scenarios 
have been shown with occasional PanIN-1 having CDKN2A loss or PanIN-2 having TP53 
inactivation (10). While the morphological progression of IPMNs and MCNs from low to 
moderate to high grade dysplasia is well known, the relationship of these morphologies to 
accumulating genetic abnormalities is less well characterized. However, as discussed 
later in this review the genetic events underlying IPMN and MCN formation are now 
being determined. 
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KRAS. One of the earliest and most universal genetic alterations observed in 
pancreatic cancer is activating mutations in the oncogene KRAS (11). At least 99% of 
PanIN-1 lesions harbor mutations in KRAS, suggesting its activation is an important 
initiating step in carcinogenesis of most pancreatic cancers (10). KRAS encodes a 
guanosine triphosphate (GTP)-binding protein, which functions as a key mediator in a 
variety of cellular processes, including cell survival, proliferation, and cell motility. In its 
inactive state, Ras is bound to GDP. Extracellular signaling through growth factor 
receptors triggers the removal of GDP from Ras, allowing GTP to bind. Inactivation of 
these active Ras-GTP complexes is accomplished when GTP is hydrolyzed. Activating 
mutations in the KRAS gene result in a loss of the intrinsic GTPase activity of the Ras 
protein, and consequently, constitutive signaling occurs even in the absence of 
extracellular signals (12). Activated Ras feeds into a number of signaling pathways, 
including the RAF/mitogen activated protein (MAP) kinase pathway, as well as into the 
phosphoinositide-3-kinase (PI3K)/AKT signaling pathway. Activating mutations in 
BRAF are observed in a subset of pancreatic cancers lacking KRAS mutations, resulting in 
aberrant Ras-Raf-MAPK signaling (13).  
CDKN2A.  The tumor suppressor gene CDKN2A is inactivated in over 90% of 
pancreatic ductal adenocarcinomas, with the vast majority of alterations arising as early 
as the PanIN-2 stage (14; 15). The CDKN2A gene possesses alternative splicing sites that 
result in the formation of several protein products. For example, the p14/ARF protein 
sequesters MDM2 helping to stabilize TP53 whereas the p16/INK4A protein acts to 
inhibit the formation of complexes between cyclins and cyclin-dependent kinases (CDKs) 
thus regulating progression through the G1 checkpoint in the cell cycle (16-18). 
 6 
 
Figure 1-2: Morphologic Features of Cystic Neoplasms of the Pancreas 
 
A: Intraductal papillary mucinous neoplasm (IPMN) of the main pancreatic duct. In this 
example the IPMN shows low‐grade dysplasia, with scattered papillae seen at low power 
(arrows). B: IPMN with high‐grade dysplasia. The neoplasm shows exuberant papillary 
growth that fills the lumen (Lu) of the main pancreatic duct.  C: Low power view of a 
mucinous cystic neoplasm (MCN). The neoplasm is distinct from the surrounding 
pancreatic acinar tissue (Ac). D: High power view of the region outlined in panel C 
showing low cuboidal mucinous epithelial lining and underlying ovarian‐like stroma.
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In about 40% of cases, inactivation of CDKN2A occurs through homozygous deletion. 
Intragenic mutation with subsequent loss of the second allele acts as a second mechanism 
for CDKN2A loss, accounting for another 40% of alterations. Methylation of the 
promoter region of CDKN2A, resulting in gene silencing, has also been observed (14).  
TP53. Inactivation of the TP53 gene is observed in higher-grade, PanIN-3 lesions 
(19). Up to 85% of pancreatic cancers have TP53 inactivation, with the most frequent 
mechanism of inactivation being intragenic mutation with loss of the second allele (20; 
21). TP53 functions as an essential regulator of many interrelated cellular processes 
including apoptosis, cell cycle progression and DNA repair. In response to DNA damage, 
TP53 can promote the transcription of p21, a CDK inhibitor that can bind to cyclin-CDK 
complexes, leading to cell cycle arrest in the G1 phase. TP53 can also regulate 
transcription of both pro and anti-apoptotic genes. Loss of TP53 results in an overall 
increase in genomic instability, as cells are permitted to proliferate in the setting of 
otherwise catastrophic DNA damage (22).  
SMAD4. As is seen with TP53, SMAD4 loss is observed in high-grade PanIN-3 
lesions (23). Inactivation of SMAD4, either by homozygous deletion or intragenic 
mutation with the loss of the second allele, occurs in ~55% of pancreatic ductal 
adenocarcinomas (24). The Smad4 protein plays a key role in propagating extracellular 
signals through the transforming growth factor β (TGFβ) signaling pathway. TGFβ 
regulates cell proliferation and differentiation, and thus acts as a critical tumor suppressor 
in normal cells. Activation of this pathway begins with binding of a TGFβ ligand to type 
I and type II serine/threonine kinase cell surface receptors. This results in receptor 
dimerization and activation of the type I receptor leading to its phosphorylation of the
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Figure 1-3: Genetic Progression Model of Pancreatic Carcinogenesis 
The molecular alterations that accumulate during pancreatic carcinogenesis can be classified into 
early (telomere shortening and activating mutations in KRAS2), intermediate (inactivating 
mutations or epigenetic silencing of CDKN2A) and late (inactivating mutations of TP53 and 
SMAD4) events. Mutations in additional genes may also occur during PanIN formation but are 




Smad2 and Smad3 proteins. Smad4 complexes with phosphorylated Smad2/3 proteins 
and together they translocate into the nucleus where, in association with transcriptional 
cofactors, regulate the expression of genes involved in a variety of important cellular 
processes including cell cycle control, cell differentiation and growth (25). Loss of 
SMAD4 and hence canonical TGFβ signaling in pancreatic ductal adenocarcinomas 
results in the loss of TGFβ-induced growth inhibition (26), and correlates with both poor 
prognosis and the development of widespread metastases in patients (25; 27; 28).  
Observations from Exomic Sequencing Approaches 
Genetic alterations in KRAS, CDKN2A, TP53, and the TGFβ family were initially 
elucidated using candidate gene approaches, namely dideoxy (Sanger) sequencing.  
However, in recent years next generation sequencing methodologies have been used to 
examine the entire coding fraction of the genome (i.e. the “exome”) with the goal of 
identifying the entire compendium of somatic alterations in this tumor type (20).  This, in 
turn, has contributed to creating a more comprehensive genetic landscape by uncovering 
both gene “mountains” and “hills”, i.e. genetic alterations that are observed in a high and 
low frequency of tumors, respectively (29). 
The Landscape of Pancreatic Cancer. A total of 20,661 protein-coding genes 
have been analyzed in 24 pancreatic cancers (20), leading to identification of a total of 
1562 somatic alterations. The majority of these changes were found to be base 
substitutions; however, small insertions and deletions as well as alterations within the 
untranslated regions (UTRs) and at splice sites were also observed.  Over 1300 genes 
were found to contain at least one genetic alteration, with 148 genes containing two or 
more alterations. Copy number analysis was also utilized to interrogate gene deletion and 
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amplification events, and revealed a total of 198 homozygous deletions and 144 focal 
high-copy amplifications in the 24 tumors analyzed. Genes within these regions of 
deletion or amplification included well-established tumor suppressors and oncogenes, 
respectively; however, additional genes that had not been previously associated with 
pancreatic ductal adenocarcinoma were also found.   
A list of candidate cancer genes (“CAN” genes) was generated based on the set of 
genes harboring somatic alterations (20). This analysis was based largely on passenger 
mutation rates, gene mutation type and frequency. Importantly, this list included each of 
the previously identified genes known to play a role in pancreatic carcinogenesis (KRAS, 
CDKN2A, TP53 and SMAD4) indicating the robustness of this approach.  Genes not 
previously appreciated in this tumor type were also identified, for example MLL3. The 
significance and roles of each of these CAN genes remains to be determined in functional 
systems; however, new studies of these genes in various tumor types is shedding light 
onto emerging processes and pathways involved in tumorigenesis (30-32).  
Core Signaling Pathways of Pancreatic Cancer. Further categorization of the 
somatic alterations data generated by whole exome sequencing revealed that they 
correspond to 12 core signaling pathways (Figure 1.4). Many of these pathways consist 
of genes that have already been appreciated as players in pancreatic cancer formation and 
progression, such as DNA damage control (TP53), cell cycle regulation (CDKN2A) and 
TGFβ signaling (SMAD4). Most importantly, the authors were able to show that while 
most patients’ carcinomas exhibited a genetic alteration corresponding to each of the 12 
core pathways, the specific gene mutated for a given pathway in each patient often 
varied. This finding may help account for both the heterogeneous nature of tumors, as 
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well as offer insight into why agents targeting a specific gene in a pathway rarely result in 




Figure 1-4: Core Signaling Pathways in Pancreatic Cancer 
The 12 pathways and processes whose component genes were genetically altered in most 
pancreatic cancers based on whole exome sequencing 20 are shown in black, and the pathway 
more recently identified in pancreatic cancer in gray 31–34. Therapeutic targeting of one or more 
of these pathways, rather than specific gene alterations that occur within a pathway, provides a 
new paradigm for treatment of pancreatic cancer. GTPase, guanosine triphosphatase; TGF‐β, 
transforming growth factor β. 
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The TGFβ Signaling Pathway 
As depicted in Figure 1.4, the TGFβ signaling cascade is one of the 12 pathways 
and processes whose constituent genes are mutated in pancreatic cancers (20).  SMAD4 
alterations (as discussed above) are the most frequently observed mutations in this 
pathway in PDA; however, loss of other components of the cascade have been noted (24).  
These include the upstream receptors TGFβ receptor 1 (TGFβR1), TGFβ receptor 2 
(TGFβR2), and bone morphogenetic protein receptor 2 (BMPR2) (20; 33; 34). 
Additionally, alterations in the receptor-regulated SMAD (R-SMAD) gene SMAD3 have 
been described, albeit infrequently (35). Upregulation of the inhibitory SMADs (SMAD6 
and SMAD7), which negatively regulate pathway signal transduction by competitively 
binding with upstream receptors, has also been shown (36; 37). Pancreatic tumors have 
also been found to overexpress TGFβ ligands, which can act directly on tumor cells if the 
receptors have not been inactivated, as well as on neighboring stromal and immune cells 
(38). 
 Canonical and Non-canonical TGFβ Signaling. The TGFβ superfamily of 
proteins consists of bone morphogenetic proteins (BMPs), TGFβs and activins (39). The 
pleiotropic nature of the pathway is a direct result of the number of different ligands that 
can activate the signaling cascade and the equally diverse set of transcription factors that 
complex with the SMAD proteins within the nucleus (40). Classical TGFβ signaling is 
initiated when TGFβ ligands bind to serine/threonine kinase receptors. The signal is 
propagated through SMAD transcription factors that form a complex prior to entering the 
nucleus to regulate gene transcription. As described above, TGFβ ligand-mediated 
signaling is mediated by the SMAD2/SMAD3 R-SMADs associating with the co-SMAD, 
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SMAD4. In the case of the BMP-mediated branch of the pathway, signaling is carried out 
by a different set of R-SMADs (SMAD1 and SMAD5), which complex with SMAD4 
prior to entering the nucleus. Pathway activation results in the transcription of target 
genes important in the regulation of critical cellular processes including the cell cycle, 
cell differentiation, apoptosis, extracellular matrix formation, and immunoregulation (39-
41).   
 In addition to the SMAD-dependent signaling cascade, TGFβ ligand binding 
triggers the activation of other signaling pathways within the cell. These include the p38 
MAPK, Erk, JNK, and Rho-like GTPases (39). TGFβ-mediated signaling through Rho-
like GTPases is known to be important in actin polymerization and cell adhesion, both of 
which are critical for cancer cell metastasis (39; 42; 43). Interestingly, these SMAD-
independent pathways have also been shown to regulate key components of the canonical 
arm. For example, JNK and Erk signaling can facilitate the activation of different SMAD 
family members (44). Additionally, Ras/Erk MAPK signaling through TGFβ-ligand 
binding results in the production of more TGFβ ligand, allowing for continued pathway 
activation even when canonical signaling is lost (i.e. SMAD4 mutation) (45).  
The Dual Role of TGFβ in Cancer. As described above, the TGFβ signaling 
pathway is responsible for regulating critical tumor suppressive mechanisms in normal 
cells (40). TGFβ regulates the expression of important inhibitors of cell cycle 
progression, p15 and p21, resulting in cell cycle arrest in the G1 phase (46; 47). TGFβ 
signaling is also important for inducing apoptosis; however, the mechanisms of this 
regulation are not fully characterized. Signaling through the pathway has been reported to 
mediate the expression of several pro-apoptotic (Bmf and Bim) and anti-apoptotic factors 
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(Bcl-2) (48-50).  In addition to these cell-autonomous mechanisms of tumor suppression, 
TGFβ also exerts paracrine effects that aid in preventing tumor formation (40). Using a 
mouse model with targeted deletion of TGFβR2 in fibroblasts, Bhowmick et al. was able 
to demonstrate increased proliferation of neighboring prostate epithelial cells and the 
eventual formation of intraepithelial neoplasia. TGFβR2-deficient fibroblasts secreted 
excess hepatocyte growth factor, which could then act on adjacent prostate epithelial 
cells, facilitating their proliferation (51). In addition to paracrine signaling that suppresses 
epithelial cell proliferation, TGFβ signaling can indirectly prevent tumor formation by 
limiting inflammation (40). Rudolf Virchow first hypothesized a link between chronic 
inflammation and the development of tumors in the 1860s (52). Today, it is well accepted 
that a subset of cancers arise from chronic infections, with inflammation being a defining 
characteristic of such processes (52; 53). Immune cells are potent producers of cytokines, 
chemokines, reactive oxygen and nitrogen species, and digestive enzymes, which 
together provide a supportive milieu for tumorigenesis (53). TGFβ is a key regulator of 
immune cell migration, differentiation, and survival, and as such, can inhibit tumor 
formation by suppressing chronic inflammation (40; 54). 
In addition to the tumor suppressive capabilities of the TGFβ signaling pathway, 
many studies have highlighted the importance of this pathway in progression and 
metastasis (40; 55). As was noted with the tumor suppressive aspects of TGFβ signaling, 
these tumorigenic mechanisms occur within the tumor cells themselves as well as via 
paracrine signaling between tumor and stromal cells. TGFβ is known to promote 
epithelial-mesenchymal transition (EMT), a process thought to be critical for invasion 
and metastasis. During EMT, epithelial tight junctions are lost, and the actin cytoskeleton 
 15 
is reorganized (56). This process is governed by several transcription factors that control 
the expression of epithelial and mesenchymal genes, including Twist, Zeb-1, Snail and 
Slug (57). While canonical TGFβ signaling is known to regulate the expression of these 
transcription factors, several SMAD-independent pathways have been implicated in 
TGFβ-driven EMT, including Erk/MAPK, mTOR, and RhoA GTPase activity (58-60). 
Coupled to its role in EMT, TGFβ reshapes the extracellular matrix by increasing levels 
of key digestive enzymes such as matrix metalloproteinases (MMPs) (61).  
The paracrine effects of TGFβ produced from tumor cells have prominent 
consequences on the tumor microenvironment. As already noted, TGFβ is a potent 
immunosuppressive cytokine that regulates immune cell recruitment, differentiation, and 
survival (62; 63). Important for tumor progression, TGFβ can directly impede T-cell 
mediated tumor cell killing by inhibiting the production of perforin and granzymes (64). 
Moreover, it is known to suppress MHC I and II expression on cells, further contributing 
to a loss in immunosurveillance (65).  Equally important, TGFβ is indispensible for the 
differentiation of T regulatory cells (66). T regulatory cells in the tumor 
microenvironment further contribute to immune tolerance by inhibiting cytotoxic T cell 
function (54). The immunoregulatory effects of TGFβ are not limited to the lymphoid 
compartment. Several groups have demonstrated increased myeloid cell recruitment to 
tumors where TGFβ signaling has been abrogated (67; 68). Additionally, TGFβ 
influences neutrophil chemotaxis, macrophage differentiation, and inhibits macrophage-
mediated tumor cell killing (69).  
Another way TGFβ signaling influences the tumor microenvironment is by 
contributing to stromal cell deposition (40). Specifically, TGFβ is responsible for 
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myofibroblast differentiation (70). Myofibroblasts are critical for tumor cell invasion, and 
are also notable for producing enzymes necessary for extracellular matrix remodeling, 
and cytokines and chemokines that facilitate tumor and immune cell migration and 
angiogenesis (71).  
In summary, a number of studies lend support to a dual role for TGFβ signaling in 
carcinogenesis. In normal cells and during early tumor formation, the suppressive arm of 
this pathway works to inhibit proliferation and inflammation, and promotes apoptosis 
(40; 69). Tumors are able to override these tumor suppressive capabilities, often by 
activating oncogenic signaling pathways such as Ras/Erk (72). After deactivating the 
tumor-suppressive arm, tumors can subsequently harness the tumor-promoting functions 
of TGFβ to facilitate invasion and metastasis (40). Tumors that acquire mutations to 
upstream receptors effectively abolish pathway signaling; however, they can still utilize 
TGFβ ligand to promote progression via paracrine signaling that alters the surrounding 
tumor microenvironment (54). In contrast, some tumors are able to selectively inhibit the 
tumor suppressive arm of the pathway, retaining metastasis-promoting functions (73; 74). 
Additionally, as was the case in the former example, these tumors can utilize TGFβ 
paracrine signaling to further facilitate invasion and metastasis. The mechanistic basis for 
the dual role of TGFβ in carcinogenesis has garnered further attention in recent years, and 
a more complete understanding is necessary if we hope to be able to target this pathway 
in patients.  
The Immune Reaction in PDA 
  In recent years, a number of studies have shed light on the complex 
interdependence of the primary tumor and its surrounding microenvironment (75-77). 
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The tumor microenvironment consists of a vast array of cells, including fibroblasts, 
endothelial cells, and infiltrating immune cells (78). One of the defining features of PDA, 
desmoplasia, illustrates the importance of tumor-stromal interactions in tumor formation 
and progression (79). This widespread stromal deposition, which can constitute nearly 
80% of the tumor, is a direct consequence of mediators secreted from tumor cells 
(including TGFβ-mediated factors, as described above). In turn, this dense stromal 
network of cells impacts tumor proliferation and invasion through secretion of digestive 
enzymes and chemokines and cytokines that are instrumental in the recruitment and 
polarization of immune cells within the tumor (79-81).  
The role the immune system plays in cancer development and progression is 
complex. For one, as already mentioned chronic inflammation is thought to play a tumor-
promoting role in a variety of cancers (54). However, it is also well established that the 
immune system is an essential tumor-suppressive mechanism as it can recognize and 
eliminate altered neoplastic cells (82). Additionally, research has demonstrated that 
various immune cells are present within precursor lesions and primary tumors, although 
the exact composition varies tremendously from one patient to the next (83-85). In PDA, 
many groups have been able to demonstrate that progression from precursor lesions to 
invasive carcinoma is characterized by notable changes in immune infiltrate (86; 87). 
Moreover, immune infiltrate in PDA tumors has been correlated with clinical outcome, 
with patients possessing increased numbers of infiltrating CD8+ cytotoxic T cells faring 
better than patients with a more immunosuppressive infiltrate (T regulatory cell 
dominant) (88; 89). These differences in immune infiltrate require special recognition 
when considering the potential benefits of immune-based therapies in patients. Below, we 
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will review the two major subsets of immune cells, lymphoid and myeloid, highlighting 
their roles in PDA initiation, progression and metastasis.  
Tumor-Infiltrating Lymphocytes. Effector lymphocyte populations largely mediate 
the anti-tumor immune response. Major cell types include CD4+ and CD8+ T cells, B 
cells, and natural killer (NK) cells. Each of these major subsets can exert anti-tumor and 
pro-tumor functions, and the predominant response is largely shaped by the cytokines 
present in the surrounding milieu (90). In PDA, a sizeable CD4+ T cell infiltrate has been 
observed; however, the majority of these cells tend to be tumor-promoting, 
immunosuppressive T regulatory cells. T regulatory cells have been shown to infiltrate in 
early, precursor stages in both human tissue samples and animal models of PDA (86; 88; 
91). These cells serve as significant inhibitors of the anti-tumor immune response as they 
can directly suppress CD8+ T cell-mediated tumor killing and contribute to immune 
tolerance. They further enhance tumor progression via secretion of key cytokines, 
including TGFβ (66). In contrast, PDA tumors often have few effector CD8+ T cells, NK 
or classical B cells, with the highest numbers often being seen in early precursor lesions 
(86; 92; 93).       
Tumor-Infiltrating Myeloid Cells. The predominant infiltrate observed in PDA 
tumors is myeloid in nature. This includes infiltrating macrophages, neutrophils, and 
immature myeloid-derived suppressor cell (MDSC) populations (86). As was described 
with lymphoid cells, myeloid immune populations can either be classically activated 
(anti-tumor) or alternatively activated (pro-tumor), with polarization being dictated by the 
local cytokine environment (94). Monocytes that arrive in the tumor microenvironment 
often differentiate into alternatively-activated macrophages (M2) or MDSCs. Animal 
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models of PDA indicate that M2 macrophages infiltrate tumors in precursor stages, and 
can contribute to tumor progression by facilitating angiogenesis and invasion (86; 95). 
Additionally, macrophages secrete various cytokines and chemokines responsible for 
recruitment and polarization of other infiltrating immune cells (96). MDSCs are a 
heterogeneous population of immature myeloid cells. In mice, they are marked by 
expression of Gr-1 and CD11b (97; 98); however, in humans it appears that various 
subsets of these cells exist, each with their own set of markers (84; 85; 99; 100). MDSCs 
are characterized by their ability to produce anti-inflammatory cytokines. Their presence 
in tumors contributes to the tumor’s ability to evade the immune system from attacking 
and destroying altered cells. Additionally, like T regulatory cells, MDSCs function as a 
significant barrier to effective immunotherapies (101). In addition to their respective 
effects on shaping the local tumor microenvironment, macrophages and MDSCs work to 
promote immune tolerance by inhibiting effector lymphocyte-mediated tumor cell killing. 
In support of this idea, studies in animal models have indicated a reciprocal relationship 
between infiltrating lymphocytes and infiltrating myeloid cells exists. In precursor 
lesions, lymphocytes are more abundant but their numbers and functionality are 
compromised as myeloid cells accumulate within the tumor stroma (86).  
 Neutrophil infiltration in PDA tumors has been correlated to decreased survival in 
patients (102). Normally, neutrophils function to kill invading pathogens – a process 
mediated by their ability to secrete reactive nitrogen and oxygen species and digestive 
enzymes (103). In the context of tumor progression, these same factors are important in 
extracellular matrix remodeling and tumor invasion (104; 105).  
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Tumor infiltrating immune cells have the potential to suppress and/or kill tumor 
cells; however, in PDA they are often linked with tumor-promoting functions (106). As 
was described above, the TGFβ signaling pathway has profound effects on skewing 
immune cell infiltrate in tumors (69; 81). Importantly, the predominant myeloid and T 
regulatory cell infiltrate found in PDA tumors can also strongly influence autocrine and 
paracrine TGFβ signaling networks (further exacerbating tumor progression, invasion and 
metastasis) as these cells are significant producers of TGFβ ligand (40).   
Animal Models of PDA 
As has been alluded to throughout this chapter, researchers have utilized mouse 
models of PDA to answer fundamental questions about the biology of this disease. 
Detailed histological and genetic studies of human tumor tissues resulted in the 
progression model of PDA described in Figure 1.3 (3; 107). Using the information 
gleaned from this model, many groups have worked to generate mouse models that could 
faithfully recapitulate various aspects of human PDA (108).  The types and numbers of 
models has grown over the years, each possessing advantages and limitations, but all 
have offered invaluable insight into PDA carcinogenesis. As a brief summary, these 
mouse models can be divided into one of two broad categories, including genetically 
engineered models and cell line/tissue implantation models (109). The following chapters 
utilize a combination of conditional genetic mouse models and orthotopic implantation of 
murine PDA cell lines.   
Implantation Models of PDA. Various implantations models of PDA exist, with 
the factors defining them including the type of tissue used (cell line versus tissue; human 
versus mouse) and the location of implantation (subcutaneous, orthotopic, splenic, or tail-
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vein) (109). The use of human tissue and cell lines in implantation models has been 
carried out extensively over the years; however, a major limitation of this model is that it 
requires the use of immunodeficient mice. Thus, comprehensive studies of the immune 
response to tumor growth are not feasible (110). To overcome this problem, a number of 
tumor-derived murine cell lines have been generated from genetically engineered mice 
bred to the same genetic background, allowing for implantation in immunocompetent 
animals. 
The different sites of implantation offer unique advantages and disadvantages. 
Subcutaneous models are relatively easy to perform; however, they often fail to 
recapitulate human PDA and infrequently metastasize (111). Tail-vein implantation is an 
especially good model for metastasis, but studies on primary tumor biology are not 
possible. Orthotopic and splenic implantation models recapitulate human PDA and 
frequently metastasize, but intraabdominal cell leakage, bleeding and infections are 
possible complications with this technique (109; 112).   
Genetically Engineered Models of PDA. Genetically engineered mouse models 
offer important advantages over the implantation models described above. Notably, they 
allow for studies of all stages of pancreatic carcinogenesis, including early precursor 
lesions that can otherwise not be studied using cell lines or tumor tissues. They also allow 
for defined expression of mutant alleles to the pancreas, allowing for histologically-
relevant models that possess both tumor and stromal components. With that said, these 
models take considerably more time and resources to generate and maintain. 
Additionally, genetic manipulations of target genes occur in every cell within the 
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pancreas that expresses the chosen promoter, a phenomenon that does not occur in human 
PDA (108; 109).   
To conditionally activate or inactivate genes within the pancreas, Cre-mediated 
recombination utilizing one of two pancreas-specific promoters is often employed.  
Pancreatic and duodenal homeobox 1 gene (Pdx1) or pancreatic transcription factor 1a 
(Ptf1a) are required for pancreatic development and differentiation. Both endocrine and 
exocrine cell types express Pdx1, while Ptf1a expression is confined to exocrine cells 
(113; 114). One of the first genes to be targeted using this approach was Kras. Mice 
expressing the Cre-activated KrasG12D allele, hereafter referred to as KC mice, develop 
precursor ductal lesions that model human pancreatic intraepithelial neoplasia (PanIN). A 
small fraction of these animals (about 10%) go on to develop invasive adenocarcinoma 
with metastasis; however, latency can span 9-15 months (115).  
From here, many groups coupled Kras activation with inactivation of various 
tumor suppressor genes. One of the most commonly used PDA mouse models used today 
is known as the KPC mouse, which combines Kras activation with a mutant allele of p53 
(p53
R172H
). As was the case with the KC model of PDA, KPC mice develop PanIN 
lesions that progress to invasive ductal adenocarcinoma. Importantly, shorter latency (4-6 
months) and higher rates of metastasis are observed in the KPC model (116). 
Of particular interest for subsequent chapters, several groups have inactivated 
components of the TGFβ signaling cascade in the context of Kras activation. Izerdjene et 
al. generated LSL-KrasG12D/+;Dpc4flox/+;Ptf1aCre/+  (KDC mice), which interestingly 
developed mucinous cystic neoplasms that infrequently progressed to PDA (117). 
However, inactivation of TGFβR2 (either one or both alleles) resulted in the more typical 
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PanIN-to-PDA histological progression. KTC mice (LSL-
KrasG12D/+;Tgfbr2flox/flox;Ptf1aCre/+) develop aggressive, metastatic PDA within a 
few months of birth. Latency is slowed to 6-8 months when only one allele of TGFβR2 is 
targeted (118).  
Taken together, animal models of PDA provide important tools for researchers to 
study the initiation, progression, invasion and metastasis of PDA. Each model system 
possesses its own set of unique limitations, but they allow for the comprehensive analysis 
of tumor-stromal interactions, the immune reaction in PDA, and importantly, they offer a 
platform from which different treatment modalities can be extensively tested (108).
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Chapter 2 : Rationale and Aims 
Rationale 
Pancreatic ductal adenocarcinoma (PDA) is among the most lethal of all cancers: 
five-year survival rates are only around 6% (119). Great strides have been made in 
understanding the genetic alterations that give rise to PDA, which include activating 
mutations in the KRAS oncogene, and inactivating mutations in genes that play critical 
roles in cell cycle control, apoptosis, and TGFβ signaling (11; 14; 15; 21; 24).  The TGFβ 
signaling pathway, one of twelve pathways/processes known to be altered in PDA 
carcinogenesis, has both tumor suppressive and tumor-promoting capabilities (40). The 
complexity of this signaling cascade, with both canonical and SMAD-independent arms, 
is likely contributing to the dual roles of TGFβ in tumor prevention and progression. In 
PDA, greater than half of patients will lose SMAD4 function, which has been correlated 
to worse prognosis and a widely metastatic pattern of failure (27; 28; 120).  In contrast, 
less than 5% of patients will acquire inactivating mutations in TGFβ receptor 2 
(TGFβR2) (34); however, alterations in this upstream component of the pathway are not 
associated with a decrease in overall survival (35).   
 While the genetic alterations that occur within tumor cells undoubtedly contribute 
to its metastatic potential, it is becoming increasingly apparent that the surrounding tumor 
microenvironment plays an important role in invasion and metastasis (67; 121; 122).  The 
tumor microenvironment consists of a vast array of cells including fibroblasts, stellate 
cells, endothelial cells, and a variety of immune cells (123). A diverse immune infiltrate, 
consisting of both lymphoid and myeloid populations of cells, has been noted in patient 
 25 
tumor samples as well as within tumors of murine models of PDA (86; 88; 91).  These 
immune cells can have both anti-tumor and tumor promoting functions, with the 
proportions and nature of infiltrating immune cells largely being shaped by the 
surrounding milieu (124-126).  In particular, TGFβ ligand acts within the tumor 
microenvironment by regulating immune cell recruitment to tumors and by polarizing 
immature immune cells when they infiltrate lesions (81).  Tumor infiltrating immune 
cells have been shown to secrete factors such as matrix metalloproteinases (MMPs), 
which aid in tumor invasion and metastasis (67; 98; 127; 128). Additionally, populations 
of immunosuppressive cells, namely T regulatory and myeloid-derived suppressor cells, 
contribute to tumor progression by promoting an immune tolerant environment (75; 76).  
 Given that TGFβ signaling is associated with cancer cell and microenvironmental 
changes that can influence tumor progression, and that alterations in TGFβ signaling 
components are prevalent in PDA, we sought to understand how different TGFβ pathway 
mutations in tumor cells influence tumor microenvironmental changes, and in turn, how 
these changes within the stromal compartment of the tumor promote metastatic efficiency 
in PDA.  The major goals of this thesis were to address how mutations in TGFβR2 and 
SMAD4 alter metastatic progression, and what immune infiltrate changes occur in the 
context of these mutations. We hypothesized that levels of TGFβ signaling underlie the 
differing metastatic propensities of PDA, and more specifically, that the patterns of 
metastatic failure seen in some patients may be explained by differences in immune 
infiltrates that are regulated by TGFβ.   
Specific Aim 1 
Determine how inactivation of TGFβR2 alters metastatic efficiency in PDA.  
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Rationale 
SMAD4 loss is common in PDA, and is associated with widely metastatic disease 
and decreased survival (28; 35). In contrast, TGFβR2 mutations are observed in 
only a small subset of patients, and are associated with better survival compared 
to patients with SMAD4 mutations (34; 35).  Additionally, the effects of TGFβR2 
inactivation on PDA metastasis have not been comprehensively studied, and such 
inactivating mutations can have different consequences than those observed with 
SMAD4 loss. To better our understanding of how TGFβ signaling promotes 
metastasis in PDA, we coupled histological analysis of human tissues with 
functional studies in a novel genetically engineered mouse model of PDA.  
Specific Aim 2 
Identify how immune populations are skewed in response to TGFβR2 inactivation in 
PDA.  
Rationale 
Aberrant TGFβ signaling has profound consequences on tumor progression (40; 
63). Within tumor cells, TGFβ pathway inactivation results in the loss of tumor 
suppressive functions, including regulation of cell cycle progression and 
apoptosis. Importantly, the effects of loss of signaling in the tumor epithelium 
extend to the surrounding stroma. These include changes in stromal architecture 
as well as in the proportions and polarization of immune cells (63; 78).  To 
identify which immune cell populations are altered in response to defects in TGFβ 
signaling, we used our novel genetically engineered mouse model of PDA 
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(Specific Aim 1) to interrogate infiltrating leukocytes via flow cytometric 
analysis.  
Specific Aim 3 
Determine what effect SMAD4 loss has on immune infiltrate in PDA, and whether 
immunosuppressive cells in SMAD4-deficient tumors alter metastatic propensity.  
Rationale 
Activation of TGFβ receptors initiates both SMAD-dependent (canonical) and 
SMAD-independent (non-canonical) signaling networks.  Loss of TGFβR2 
function (examined in Specific Aims 1 & 2) results in abrogation of both 
canonical and non-canonical cascades whereas in the context of SMAD4-
deficiency, SMAD-independent signaling is retained (39; 40). To determine 
whether SMAD-independent signaling networks influence the immune infiltrate 
in PDA tumors, we generated SMAD4-deficient tumor cells and implanted them 
directly into the pancreata of mice.  Additionally, given that SMAD4 loss is 
correlated with widely metastatic PDA, we explored whether immunosuppressive 
cells from SMAD4-deficient tumors contribute to metastatic efficiency.   
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Significance 
Pancreatic cancer is among the most lethal of all cancers. In 2014, the National 
Cancer Institute estimates that 46,420 people in the United States will be diagnosed with 
pancreatic cancer and 39,590 patients will die from the disease (119). An overwhelming 
majority of these patients, as high as 80%, are diagnosed when the primary tumor has 
already metastasized either locally or to distant sites (119). Treatment options for these 
advanced-stage patients are severely lacking. Surgical resection is rarely offered to 
patients with metastatic disease (129), and the accepted combination therapies of either 
FOLFIRINOX or Gemcitabine coupled with Abraxane extend survival by less than six 
months compared to Gemcitabine alone (130; 131).  
Improving the bleak prognosis inherent to PDA requires a more comprehensive 
understanding of the mechanisms of metastasis. Overall, this study aims to answer how 
perturbed TGFβ signaling influences progression and metastasis in PDA, as well as offer 
insight into the complex tumor cell-stromal cell interactions that work to mediate these 
processes.  
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Chapter 3 : Cell-Autonomous TGFβ Signaling in Pancreatic 
Cancer Uncouples Primary Tumor Growth from Organ-
Specific Colonization Through Secretion of Prometastatic 
Mediators. 
This work is submitted for publication. 
 
Y Zhong, A Macgregor-Das, T Saunders, A Makohon-Moore, J Poling, L Cope, S Leach, 
and C Iacobuzio-Donahue.  Cell-Autonomous TGFβ Signaling in Pancreatic Cancer 
Uncouples Primary Tumor Growth from Organ-Specific Colonization Through Secretion 




























Abundant epidemiologic and clinical data indicate that pancreatic ductal adenocarcinoma 
(PDA) is a highly lethal disease with a current five-year survival rate that barely 
surpasses 6% (132).  Most diagnoses are made well after the tumor has invaded into 
surrounding vital structures or disseminated at which time there is a paucity of treatment 
options (133). The current understanding of PDA metastasis, like other solid tumors, is 
that cells from the primary tumor intravasate into vessels, disseminate within the 
circulation and extravasate into distant sites where a minority may establish secondary 
lesions (134).  Genomic studies and computational models also indicate that clinical 
metastasis is a late event in the clonal evolution of PDA (135; 136), although compelling 
data in transgenic models suggests that some aspects of this process occur before the 
advent of invasive ability (137). However, beyond this framework, the actual 
mechanisms by which PDA metastasizes remains unknown.  Ultimately, the dismal 
survival statistics faced by newly diagnosed patients can only be improved with a more 
complete understanding of the biology of PDA metastasis.  
Comprehensive analyses of PDA indicate that it is a genetically complex disease 
(20; 138).  Like other epithelial cancers, PDA arises from the accumulation of somatic 
alterations in a distinct set of driver genes (139) upon which additional somatic 
alterations occur over time and geographic space (136). These driver genes, KRAS, 
CDKN2A, TP53, and SMAD4, arise during pancreatic intraepithelial neoplasia (PanIN) 
from which an infiltrating carcinoma may develop (140). Additional cell-autonomous 
mechanisms that contribute to PDA behavior include aberrant activation of 
developmental signaling pathways (141; 142), alterations in cellular metabolism (143; 
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144) or a dependence on autophagy (145).  The dynamic stromal reaction characteristic 
of PDA and associated immunosuppressive environment may further contribute to its 
aggressive biology (reviewed in (146)). 
In previously reported autopsy series of patients with documented infiltrating 
PDA of the pancreas, a subset were identified that had low metastatic burdens, and in 
some cases no metastases despite prolonged survival, suggesting the existence of a form 
of pancreatic cancer with low metastatic propensity (28). In an effort to understand this 
phenomenon, we used a combination of classical morphologic studies of human tissues, 
transgenic mouse models and functional metastasis assays as a platform for delineating 
the mechanisms of metastatic efficiency of PDA.   
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Materials and Methods 
Antibodies 
Primary antibodies raised against CD31 were purchased from Life Span Biosciences (LS-
B1932); Keratin 17/19 (#3984), pHH3 (#9701), P-p44/42 MAPK (pERK, #4376) were 
purchased from Cell Signaling Technology; SHH was purchased from R&D Systems 
(AF464); Muc5AC (Sc-21701), TGFBR2 (L-21, SC-400), COL6A1 (H200, sc-20649), 
NGAL (M-145, sc-50351), E-cadherin (G-10, sc-8426) was purchased from Santa Cruz 
Biotechnology; Fibronectin was purchased from Abcam (ab23750); SMA was purchased 
from Dako (1A4); CD10 (PA5-23701) was purchased from Thermo Fisher Scientific); 
LGAL53BP (Bs-5729R) was purchased from Bioss Antibodies.  
 
Human Tissues 
Postmortem primary and metastatic pancreatic cancer tissues from consenting patients 
were obtained following IRB approved protocols previously described in detail 
(Embuscado et al., 2005).  
Mouse strains  
The conditional LSL-KRAS
G12D
 mice (147), 129S4-Trp53tm2Tyj (148), B6.129S6-
Tgfbr2tm1Hlm (149) and Ptf1a
tm1.1(cre)Cvw 








obtained from Jackson Laboratories.  The Ptf1a
tm1.1(cre)Cvw 
mice were purchased from 
MMRRC (Mutant Mouse Regional Resource Centers). Mice were genotyped by PCR 
using primers specific to transgenic alleles (conditions available on request).  This study 
was approved by the Animal Care and Use Committee. 
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Mouse Histology and Immunohistochemistry 
Normal tissues, pancreata and metastatic cancer tissues of moribund mice or mice at 
specific age timepoints (4, 8, 12 weeks) were fixed with 10% buffered formalin solution 
overnight and embedded into paraffin by the Johns Hopkins Reference Histology 
Laboratory. Sections cut from each paraffin block were stained with hematoxylin and 
eosin following standard protocols and observed under a light microscope for diagnoses.  
For immunolabeling, unstained 5-m sections were cut from paraffin blocks and the 
slides deparaffinized by routine techniques followed by incubation in 1x sodium citrate 
buffer (diluted from 10 x heat-induced epitope retrieval buffer, Ventana-Bio Tek 
Solutions, Tucson, AZ) before steaming for 20 minutes at 80 C. Slides were cooled 5 
minutes and incubated for two hours to overnight with primary antibody. 
Immunolabeling was detected using the Ventana IVIEW Kit per kit instructions and 
sections were counterstained with hematoxylin. 
Cell Staining for Immunofluorescence Microscopy 
Cells grown on coverslips were fixed in 3.7% or 4.0% paraformaldehyde solution for 30 
minutes at 37°C. All subsequent steps were carried out at room temperature. Coverslips 
were incubated with E-cadherin monoclonal antibodies (1:100 dilution; Santa Cruz) in 
PBS-1% BSA for 1 h and followed by incubation together with FITC-conjugated goat 
anti-mouse secondary antibody (Sigma). Coverslips were mounted in Prolong Gold 
Antifade reagent with DAPI (Molecular Probes), and images were captured with a Zeiss 
fluorescence microscopy system. 
Cell proliferation assay 
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All cells were cultured in DMEM (GIBCO, Invitrogen Life Technologies, Carlsbad, CA, 
USA) supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, 100 
-glutamine at 37 
o
C and 5% CO2. Cell proliferation 
assay was performed using cell counting Kit-8 (Dojindo Molecular Technologies, Inc., 
Gaithersburg, MD, USA) according to manufacturer protocols. Absorbance was 
measured at 490 nm using a microplate reader.  Each experiment was carried out in 
triplicate.   
Experimental Metastasis Assays 
KPC and KPTC cell cultures were dissociated into single cell suspensions in PBS, 
counted, and injected into the tail veins of C57/B6 mice (5 x 10
5
 cells per mouse).  After 
three weeks the animals were euthanized and their lungs removed, rinsed in PBS and the 
number of gross (surface) pulmonary nodules counted using a dissecting microscope.  
Quantitative Secretome Analysis  
KPC and KPTC cells were grown to confluence in tissue culture dishes, washed with 
serum-free media eight times and incubated in serum-free media for 24 hours. The 
conditioned media (CM) was harvested and centrifuged to eliminate any intact cells and 
the supernatants were then concentrated and desalted by centrifugation in Amicon Ultra-
15 tubes (molecular weight cutoff 3000 Da; Millipore, Billerica, MA).  Protein samples 
were quantified and analyzed by the Proteomics Core Facility of Johns Hopkins.  The 
protein concentrations of KPC and KPTC CM samples were labeled with the iTRAQ 
reagent (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s 
protocol, and then subjected to MS/MS analysis. Data analysis on the data files from the 
LC-MS/MS were performed with the Thermo Scientific™ Proteome Discoverer™ 
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Software (Thermo Fisher Scientific, Inc., Waltham, MA). The identified proteins were 
further subjected to bioinformatic analysis.  Proteomics data have been deposited in the 
Peptide Atlas Database with the accession number PASS00575. 
Quantitative Real Time PCR  
Total RNA was extracted from tissue samples using RNeasy mini Kit (Cat. No., 74104; 
Qiagen). RNA was treated with DNase I (Invitrogen) to digest remnant genomic DNA. 
System (Invitrogen) according to the protocol recommended by the manufacturer. For 
quantitative PCR, one microgram of RNA per sample was reverse transcribed into cDNA 
using SuperScriptTMIII Platinum® Two-Step qRT-PCR Kit (Invitrogen) according to 
the protocol recommended by the manufacturer. Real-time quantitative RT-PCR analysis 
was performed using an automated sequence detection instrument (7300 Real Time PCR 
System, Applied Biosystems, CA, USA) for the real-time monitoring of nucleic acid 
green dye fluorescence (SYBR®Green, Invitrogen Inc, CA, USA). Relative fold-changes 
of analyzed gene expression compared to the housekeeping gene β-actin were determined 
by calculation of the 2
ΔΔCt
.  All analyses were performed in triplicate at least 2 times.  
Primer sequences will be provided upon request.  
Western Blotting Assay 
Cell lysates were prepared by suspending cell pellets in RIPA buffer (20 mM Tris, 0.1% 
SDS, 1% Triton X-100, 1% sodium deoxycholate, pH 7.4) supplemented with protease 
inhibitor cocktail tablets (Roche diagnostics GmbH, Mannheim, Germany).  Equal 
amounts of proteins were separated on SDS-polyacrylamide gel and transferred onto 
PVDF membranes (DuPont NEN, Boston, MA). Each membrane was hybridized with 
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primary antibody followed by horseradish peroxidase (HRP)-linked IgG and visualized 
by the enhanced chemiluminescence (ECL) system (Amersham).  Expression of β-actin 
or GAPDH were used as internal controls. 
Stable shRNA knockdowns and Stable over-expression   
COL6A1 shRNA (TF500404, Origen) and cDNA plasmid (MG223027, Origen) LCN2 
shRNA (TG511895, Origen) and cDNA plasmid (MG226233, Origen) were purchased 
from Origen. KPC and KPTC cells were cultured in Dulbecco's modified medium 
containing 10%FBS. Plasmid DNA transfection of cells was performed by using 
Attractene reagent (Cat. No., 301005, Qiagen) following the Reverse transfection 
protocol. 48 hours after transfection, passage the cells into the appropriate selection 
medium, maintain the cells in selective culture medium until colonies appear. Inhibition 
of gene expression by shRNA and over-expression of target gene were determined by 




Expression of TGFβ Pathway Components Correlates with Metastatic Behavior in 
Human Pancreatic Cancer 
To determine the extent to which there are morphologic features that define 
oligometastatic PDA (patients with 0-10 gross metastases) (28) we reviewed histologic 
sections prepared of the primary carcinoma for six patients with this phenotype at 
autopsy (Table 3.1).  Nine primary carcinomas from patients from the same autopsy 
series who had widely metastatic PDA (>10 gross metastases) were similarly studied.  
All 15 patients were untreated, largely an unfortunate consequence of their late diagnosis, 
allowing us to definitively exclude treatment related changes to the tumor tissues 
examined. 
Primary tumor tissues from oligometastatic PDAs showed evenly dispersed well 
to moderate differentiated neoplastic glands with organized lumina and basally located 
nuclei (Figure 3.1A, 3.1B and Figure 3.2A).  Infiltration by single cancer cells into the 
surrounding stroma was uncommon and when seen was localized to discrete microscopic 
foci (Figure 3.2A).  None of the PDAs were mucin producing (colloid carcinomas). The 
stromal response was robust and contained abundant collagen deposition admixed with 
glycosaminoglycans as evidenced by a Movats pentachrome stain; αSMA, a marker of 
activated stellate cells (151) was also diffusely positive throughout the stromal 
compartment (Figure 3.2C). While metastases in these patients were relatively 
uncommon (Table 3.1), when present their histologic features were similar to that of the 
matched primary carcinoma, indicating the morphologic characteristics of the neoplastic 
epithelium were persistent in the secondary sites (Figure 3.2D). By contrast, tissues from 
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the primary tumors of widely metastatic disease revealed a predominance of neoplastic 
glands with poorly formed lumina, syncytial growth, intraluminal necrosis and apoptotic 
debris (Figure 3.1A, 3.1B and Figure 3.2B).  Single cell infiltration into the surrounding 
stroma was frequent and in some carcinomas the predominant morphology (see A132, 
Figure 3.2B). However, the stromal response was similarly prominent in widely 
metastatic PDAs based on αSMA and pentachrome stains (Figure 3.2C).  Perineural 
and/or vascular invasion was also identified in both oligometastatic and widely metastatic 
PDA indicating this feature was not discriminatory of metastatic propensity in this 
sample set (Table 3.1 and Figure 3.2E). Given these differences, we next wondered if 
PDA cells in each phenotype have differences in expression of E-cadherin and vimentin, 
two general markers of epithelial versus mesenchymal phenotypes.  An immunolabeling 
survey of each carcinoma indicated that E-cadherin was expressed by all carcinomas, and 
in virtually all it was mislocalized to the cytoplasm (Figure 3.1C).  By contrast, vimentin 
was strongly expressed in 6 of 9 widely metastatic PDAs but in none of the 
oligometastatic PDAs, indicating a gain of vimentin was correlated with higher metastatic 
propensity (p=0.027, Fisher Exact Test).   
 The TGFβ signaling pathway is a master regulator of cell differentiation, growth, 
adhesion and migration during embryogenesis and in response to inflammation, including 
within the pancreas (25). Given the pronounced disparities in neoplastic cell morphology, 
cohesion and expression of vimentin between the two cohorts of samples, we 
hypothesized that levels of TGFβ signaling may account for these differences.  We 
therefore labeled tumor tissues of each PDA for TGFβ1 ligand expression, revealing a 
marked difference in overall TGFβ1 within oligometastatic and widely metastatic PDA 
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(Figure 3.1D).  Oligometastatic PDAs showed low expression within both the epithelial 
and stromal compartment; however, scattered positive labeling stromal cells were seen 
(insets A70 and A56, Figure 3.1D).  By contrast, primary carcinoma tissues associated 
with widely metastatic disease showed positive expression throughout the tumor tissues 
(A43 and A93, Figure 3.1D).  A semi-quantitative review of one complete cross-section 
of each carcinoma in a blinded manner confirmed these differences with none of five 
evaluable oligometastatic PDAs showing positive TGFβ1 labeling compared to seven of 
nine widely metastatic PDAs (p=0.021, Fisher Exact Test; see also Table 3.2). Because 
TGFβ1 ligand exerts its effects through binding to the TGFβRI/II receptor complex (41) 
we next evaluated the expression of TGFβR2 in serial sections of these same tumors 
(Figure 3.1E).  Similar to that of its ligand there was a significant disparity of TGFβR2 
expression between oligometastatic and widely metastatic pancreatic cancers, with the 
latter subset having significantly greater expression levels within the neoplastic 
epithelium (p=0.014, Fisher Exact Test; see also Table 3.2).  Collectively, these data 
indicate that a relative loss of TGFβ signaling components within PDA cells is correlated 
with the low metastatic propensity observed in some patients. 
Reduced TGFβ signaling Accelerates Carcinogenesis in a Conditional Mouse Model 
of Pancreatic Ductal Adenocarcinoma 
To determine the mechanisms by which reduced levels of TGFβ signaling in PDA 






mice by interbreeding them with Ptf1a
Cre/+
 transgenic animals (hereafter referred to as 
KPTC mice). The co-occurrence of each rearranged allele was detected in the pancreas 
but not kidneys of each compound mutant animal by allele-specific PCR (Figure 3.3A 
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and Figure 3.4).  KPTC mice were phenotypically normal at birth and born at expected 
Mendelian ratios.  
KPTC mice (n=34) exhibited a median survival of 4.4 months with 100% 
















 mice, KTC, p<0.0001; and others) 
(Figure 3.3B).  Necropsy of these mice indicated the presence of abundant hemorrhagic 
ascites in association with a fibrotic pancreatic mass (Figure 3.3C), which obstructed the 
small bowel or was infiltrative into surrounding organs (Figure 3.3D).  A subset of 
animals (n=12) also had gross evidence of metastasis to the liver, lung, peritoneum or 
abdominal lymph nodes (Table 3.3) similar to the spectrum of disease encountered in 
human PDA.  With one exception all quadruple mutant animals succumbed to infiltrating 
PDA (Figure 3.3E and Tables 3.3, 3.4). Histologic review of the pancreata from cohorts 
of KPTC mice sacrificed at predetermined intervals also revealed preinvasive lesions 
consistent with murine PanIN (mPanIN) (140). Moreover, the latency to development of 
cancer was significantly shorter in KPTC mice compared to KPC controls (Figure 3.3F). 
In KPTC mice mPanIN2 lesions were seen as early as four weeks of age; by 12 weeks of 
age 89% of mice developed mPanIN3 with a subset (22%) also developing infiltrating 
PDA.  By contrast, only 30% of KPC mice had mPanIN3 at the 12 week timepoint 
(p=0.012).  Based on these observations we conclude that TGFβ signaling restrains 
pancreatic carcinogenesis, and loss of one Tgfbr2 allele abrogated this restraint in KPTC 
mice. 
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Loss of TGFβ signaling Restrains Cell-Autonomous Oncogenic Properties of 
Invasive PDA 
We next compared the histology of the PDAs arising in KPTC mice to those 
arising in KPC mice.  Regions of ductal (well or moderately differentiated) and solid 
(poorly differentiated) growth were seen in both KPTC and KPC tumors (Figure 3.5A). 
However, infiltrating PDAs in KPTC mice were highly enriched for ductal morphology 
as supported by an increased overall frequency of well to moderate differentiation (85% 
of KPTC carcinomas versus 59% of KPC carcinomas, p=0.029, Table 3.4) and in the 
proportion of well or moderate differentiation per individual carcinoma (median 75% 
versus 50%) (p=0.0053, Figure 3.5B and Table 3.4).  Areas of ductal morphology were 
largely accompanied by a relative increase in stromal density as well based on routine 
histologic stains and labeling for αSMA (Figure 3.5A).  The presence of undifferentiated 
(sarcomatoid) carcinoma was also seen in a minority of KPTC and KPC mice, as was the 
presence of high-grade neoplasms of the cerebellum or spinal cord that caused hindlimb 
paralysis in some animals (Figure 3.6). These latter findings are likely related to neural 
Ptf1a
Cre/+
 expression as recently described (152).  
To confirm that the differences in morphology were not due to transgene 
variegation and/or mosaic Cre activity, we microdissected areas of coexistent poorly 
differentiated and well/moderately differentiated PDA from a subset of KPTC and KPC 
tumors (Figure 3.7A).  In all cases the identical genotype was present in both 
morphologies within the same carcinoma, confirming that somatic mosaicism for 
transgene activation did not account for these effects.  Furthermore, all PDAs irrespective 
of genotype or morphology showed nuclear accumulation of Trp53 protein indicating 
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universal loss of the wild type allele (Figure 3.7B). Smad4 expression was also retained 
in primary cells prepared from KPTC and KPC PDA tissues (Figure 3.7C,D).  
To understand why KPTC carcinomas showed a shift towards more differentiated 
tumors, we immunolabeled a subset of KPTC and KPC PDA for Tgfβr2 and Tgfβ1.  
Tgfβr2 was expressed in all KPTC tumors although at low power labeling was 
heterogeneous with regions of both strong and weak positive expression seen within the 
same tissue section (Figure 3.5C).  At higher power, these differences in labeling 
intensity showed a striking correlation to the extent of ductal differentiation present 
within a single PDA.  For example, areas of poor differentiation showed positive labeling 
of the neoplastic epithelial cells (Figure 3.5D) whereas geographically distinct areas of 
well to moderate differentiation in the same carcinoma showed weak to negative 
expression of Tgfβr2 within the epithelial compartment (Figure 3.5E).  Labeling was 
retained in the stromal compartment of both well to moderately and poorly differentiated 
areas (Figure 3.5E & I).  A qualitative difference in Tgfβr2 expression was noted as well 
in that labeling was cytoplasmic in poorly differentiated regions whereas in well to 
moderate differentiated regions it was localized to the apical cytoplasm (inset, Figure 
3.5E) suggesting a degree of posttranslational processing in accounting for differences in 
Tgfβ signaling as well.  By contrast, there were no quantitative or qualitative differences 
for Tgfβ1 labeling in KPTC PDA tissues (Figure 3.5F & G).  We next determined the 
extent to which variability of Tgfβr2 labeling occurs in KPC PDAs.   Similar to KPTC 
tumors, Tgfβr2 was heterogeneous in labeling intensity throughout KPC PDAs and this 
intensity also corresponded to the extent of ductal differentiation (Figure 3.5H & I).  
Labeling for Tgfβ1 was also uniform in KPC PDAs although in one carcinoma a relative 
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loss of Tgfβ1 was noted in the region of well-differentiated morphology that also had a 
complete loss of Tgfβr2 expression (KPC2, Figure 3.5J & K).   
These data suggest that there is an inherent geographic variation to the levels of 
cell-autonomous Tgfβ signaling in a single PDA, and the consequence of Tgfbr2 
haploinsufficiency in the KPTC model is a shift towards a greater proportion of 
neoplastic cells having reduced Tgfβ pathway activity.  To support this hypothesis, we 
labeled each KPTC and KPC PDA for fibronectin, a known Tgfβ target gene (153).  
Fibronectin expression within the neoplastic epithelium paralleled that of Tgfβr2, with 
higher levels of fibronectin detected in regions of poor differentiation (Figures 3.5L & N) 
and low levels of fibronectin in regions of well/moderate differentiation (Figures 3.5M & 
O) in both KPTC and KPC mice. Labeling for fibronectin was nonetheless observed 
within the adjacent stroma of all PDAs, buttressing our observation that Tgfβ signaling 
within the neoplastic compartment serves as the basis for these observations. To further 
support our hypothesis, we treated primary KPTC and KPC cells with vehicle or Tgfβ1 
ligand (Figure 3.5P).  KPC cells underwent a profound loss of E-cadherin expression and 
transformed from tight epithelial clusters to loose aggregates in the presence of Tgfβ1, 
whereas no effect was seen for KPTC cells.  Thus, unlike carcinogenesis in which Tgfβ 
signaling exerts a restraining influence, in invasive PDAs Tgfβ signaling promotes 
oncogenic behavior, thereby phenocopying our observations in human PDA. 
Reduced TGFβ signaling Limits the Efficiency of Lung Metastasis 
To determine the extent to which Tgfβ signaling affects metastatic propensity, we 
characterized the metastatic burdens in both cohorts of mice.  Despite their reduced 
median survival, KPTC mice had a paradoxical reduction in the rate of metastasis with 
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only 12 of 34 KPTC mice (35%) having any gross or microscopic evidence of metastasis 
compared to 15 of 22 KPC mice (68%) (Figure 3.8A). However, among mice with 
metastasis there was no significant difference in their observed metastatic burden.  
Moreover, in both cohorts of mice the distribution of metastases was similar with the 
lung and liver the most common sites of spread, respectively.   
As KPTC mice developed PDA at a reduced latency compared to KPC mice 
(Figure 3.3B), we asked whether earlier death due to the primary tumor was the cause of 
the lower rates of metastasis.  If so, primary cells from KPTC and KPC carcinomas 
would be expected to have similar rates of metastasis in experimental assays.  To address 
this question, we injected primary tumor cells prepared from individual KPTC or KPC 
mice into the tail veins of CD1
nu/nu
 mice followed by quantification of lung metastases.  
While these cell lines had no significant differences in cell proliferation (Figure 3.8B) or 
mRNA expression of Snail, Slug or Twist (data not shown), KPTC cell lines showed a 
markedly lower efficiency at generating lung metastases in this assay (Figures 3.8C & D, 
p<0.0001) indicating the earlier time to death of KPTC mice was not the cause of 
decreased metastasis. These findings suggested to us that loss of Tgfβ signaling in the 
primary site reduces the fitness of disseminated cells rather than reducing the rate of 
dissemination per se, and those cells with retention of Tgfβ activity are selected for 
during colonization of the lung.  Consistent with this notion, the immunolabeling patterns 
for Tgfβr2 and Tgfβ1 were similar in spontaneous lung metastases from KPTC and KPC 
mice (Figure 3.8E). 
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Reduced TGFβ signaling Limits the Ability to Form Invasive Liver Metastasis 
We next assessed the liver metastases in these same mice, the next most common 
site of metastasis in our model, to determine if this interpretation holds.  There was a 
profound difference in the morphologic features of liver metastases in KPTC and KPC 
mice (Figure 3.9A).  In KPTC mice, neoplastic cells were frequently identified within 
vascular spaces of the portal drainage system as evidenced by luminal red blood cells or 
lymphocytes (arrow, Figure 3.9B) and immediately adjacent bile ducts (Figure 3.9C & 
D).   CD31 labeling confirmed the observation of intravascular carcinoma as well as 
indicated that colonization of the portal veins by the PDA led to a replacement of the 
endothelial cells (Figure 3.9D). The intravascular cells were confirmed to be PDA by 
both CK19 expression (Figure 3.9E) and nuclear accumulation of Trp53 protein (Figure 
3.9F).  
A number of features indicated that intravascular metastases were not simply a 
reflection of dissemination caught in an early phase.  First, intravascular metastases 
greater than >1 mm in diameter were identified that nonetheless had no stromal reaction 
(Figure 3.9G & H) giving the appearance of a cystic mass with pseudopapillary features 
(Figure 3.9H); such metastases would have required numerous cell divisions to reach this 
size. Second, intravascular metastases were uncommon in KPC mice whereas invasive 
metastases were frequent, with invasion recognized by the associated stromal response 
and infiltrative growth into the liver parenchyma (Figure 3.9I).  Finally, in KPC mice 
with intravascular liver metastases, invasive metastases were also present and 
outnumbered the former by at least 10-fold (Figure 3.9J).  A quantitative assessment of 
the presence of intravascular versus invasive metastases confirmed the difference 
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between the two genotypes (eight of nine KPTC mice, 89%, with only intravascular 
metastases versus two of nine KPC mice, 22%, p=0.0076, Figure 3.9K).  Further review 
of liver metastases in these mice revealed that the one KPTC mouse with invasive liver 
metastases (KPTC18) had a metastatic sarcomatoid carcinoma and one of the KPC mouse 
with intravascular liver metastases (KPC17) only had three total gross metastases 
identified at necropsy.  We next reviewed the labeling patterns of fibronectin, indicating 
that intravascular metastases were uniformly negative for fibronectin, whereas invasive 
metastases were uniformly positive (Figure 3.9L).  Collectively, these data suggest that 
the ability of PDA cells to colonize the liver is also dependent on Tgfβ signaling.  
TGFβ Signaling Promotes Secretion of Pro-Metastatic Mediators 
The Tgfβ signaling pathway plays an important role in the crosstalk between 
cancer cells and their tumor microenvironment at the metastatic niche, which is required 
for metastatic growth in secondary sites (154). We were interested in the extent to which 
cell-autonomous Tgfβ signaling may modulate growth in secondary sites by its effects on 
the secretion of prometastatic proteins. We therefore collected the 24 hour conditioned 
media from Tgfβ stimulated KPTC and KPC cells and subjected it to iTRAQ-based 
quantitative proteomic analysis (Figure 3.10A).  More than 3000 proteins were identified 
by this approach including known Tgfβ-target genes such as Tgfβ1 and VEGF (155). 
Bioinformatic analyses to screen for the most differentially secreted proteins between 
KPTC and KPC cells resulted in a high-confidence list of 391 proteins with a false-
discovery rate ≤0.001 and a p-value ≤0.001 (subset of proteins shown in Table 3.5).   
The secretome of KPTC and KPC cells were dramatically different, as evidenced 
by the 343 proteins secreted in abundance from KPTC cells versus 48 proteins that were 
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more abundant in the secretome of KPC cells (Figure 3.10B, Table 3.5). KPC secreted 
proteins included Sdf1r and Cxcl1, both reported to promote breast cancer metastasis by 
providing cell-survival paracrine signals to disseminated tumor cells (156; 157), and 
Vcam1 that promotes organ-site specific breast and melanoma metastasis via IL-18 
dependent upregulation of endothelial growth factors or integrin α4β1 (156; 158).  
Biologically interesting proteins, some of which have putative roles in pancreatic cancer, 
were also identified including the mitochondrial protein HSP60 (156; 159) or the 
nonmuscle myosin protein MYH9 (160).  We selected two proteins, Col6A1 and Lcn2, 
for further evaluation and functional validation in KPTC and KPC cells.  Col6A1 is a 
short chain collagen involved in cell migration and differentiation related to embryologic 
development; it has also been described to be a Tgfb1 target gene in fibroblasts (161).  
Lcn2, also known as neutrophil gelatinase, plays a role in cytosolic iron-delivery in 
association with bacteriostasis and has been associated with aggressive features in several 
tumor types (162). 
Western blotting for these two proteins in total protein extracts prepared from 
KPC and KPTC cells confirmed the results of the secretome analysis, with KPC cells 
showing greater levels of expression for both Col6A1 and Lcn2 (Figure 3.10C); 
spontaneous lung metastases were also confirmed to express Col6A1 and Lcn2 (Figure 
3.10D).  However, mRNA expression of Col6A1 and Lcn2 was upregulated to a similar 
magnitude by Tgfβ1 stimulation in both KPC and KPTC cells.  This indicates that the 
Tgfβ downstream pathways responsible for promoting PDA metastasis may be different 
from those that control Col6A1 and Lcn2 expression (Figure 3.11).  To determine if these 
two proteins have a causal effect on metastasis, we tested their ability to modulate 
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experimental lung metastases.  Stable knockdown of Col6A1 in both KPC2 (Figure 
3.10E) and KPC9 (Figure 3.10F) primary cells led to significant reductions in lung 
colonization (Figure 3.10G, p=0.001; Figure 3.10H, p=0.047) compared to mice injected 
with primary cells stably transfected with a scrambled shRNA. Despite efficient 
knockdown of Lcn2 in KPC2 cells (Figure 3.10E) only a modest effect on lung 
colonization was seen (Figure 3.10G).  This supports the view that prometastatic proteins 
work as a collective unit such that knockdown of any individual protein may not have a 
robust effect (156).  By contrast, stable overexpression of Col6A1 or Lcn2 in KPTC4 
cells (Figure 3.10I) caused a marked increase in metastatic lung colonization compared to 
mock expressing cells (Figure 3.10J, p<0.0001 and p<0.0001, respectively).  Together, 
these observations indicate that the prometastatic effects of Tgfβ1 include secretion of 




The TGFβ pathway has long been known to exert both tumor suppressive and tumor 
promoting properties (40; 69). The tumor suppressive functions of this pathway stem 
from its role in cytostasis, apoptosis and differentiation; loss of these suppressive 
influences may occur through genetic or epigenetic mechanisms thus allowing the cancer 
cell to co-opt TGFβ responses for invasion, dissemination and metastatic colonization 
(40). Our data indicate that aggressive PDAs follow this paradigm, in keeping with 
findings of restrained PanIN progression in an EL-Kras/Tgfbr1
+/-
 pancreatic cancer 
mouse model (163). However, we now show strong evidence that for a subset of PDA the 
tumor suppressive effects of the TGFβ pathway are retained after carcinogenesis, the 
phenotypic consequences of which are oligometastatic pancreatic cancer (Figure 3.12).   
 Evidence suggesting the tumor-promoting role of the TGFβ pathway were shown 
by Ijichi et al in a model of aggressive pancreatic ductal adenocarcinoma based on 
conditional inactivation of Tgfβr2 in association with Kras
G12D 
expression (118).  While 
our data are entirely in keeping with their findings, they also clarify the role of Tgfβr2 by 
demonstrating that aggressive growth at the primary site is not synonymous with 
metastatic propensity, and may even have an inverse correlation, consistent with 
observations by Ostapoff using a neutralizing Tgfβr2 antibody (164).  In this regard the 
KPTC model faithfully recapitulates clinical stage III patients who are diagnosed with 
locally advanced disease in the absence of metastases, some of who may never progress 
systemically but who die from complications of infiltration into adjacent vital structures 
(28). The extent to which patients with locally advanced PDA are enriched for the 
oligometastatic phenotype or for inactivating mutations in TGFβR2 may be worthwhile to 
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determine.  Of interest, Blackford et al showed that surgically resected patients whose 
carcinomas have TGFβR2 mutations have an improved overall survival compared to 
those with SMAD4 inactivation (35) although the patterns of failure of these patients were 
unknown. 
 These findings do not minimize the roles of other critical pathways for this 
disease, including TGFβ, in the stromal compartment.  In fact, the pronounced stromal 
response in regions of low cell-autonomous TGFβ suggest an enhancement of paracrine 
regulation with potentially important consequences for stromal modulating therapies 
(165-167). These consequences relate to not only the heterogeneity of the stromal 
reaction within a single PDA, but to the heterogeneity of the stromal reaction across 
different PDAs as well. 
 The mechanisms by which the TGFβ pathway converts from tumor suppressive to 
tumor promoting appear to vary by tumor type (40). In pancreatic cancer, this shift may 
be mediated by mutation of the TP53 tumor suppressor gene given its occurrence in late 
carcinogenesis that coincides with the acquisition of TGFβ oncogenic activity (107), its 
known role in promoting metastasis (168-170), that somatic mutation of TP53 occurs at 
much higher frequency that that of SMAD4, that loss of SMAD4 is not required for the 
development of aggressive metastatic disease, and finally that patients with 
oligometastatic disease are more likely to have wild type TP53 (171). In this regard 
SMAD4 loss compounds the tumor promoting effects of TGFβ to an even greater extent, 
resulting in the most virulent form of PDA.  Given that SMAD4 loss itself may promote 
metastasis of PDA (117), the tumor promoting properties of the TGFβ pathway in the 
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setting of mutant TP53 can thus be classified as Smad4-dependent and independent (172; 
173). 
The above interpretation may also serve to explain the conclusion by Hezel et al 
that the TGFβ pathway is suppressive during progression; in that murine model a Trp53 
null allele was used and both cell-autonomous and non-cell autonomous TGFβ ligand 
was pharmacologically targeted (174). Regardless, the work by Hezel et al clearly 
demonstrates the complexities of targeting this pathway that should be taken into 
consideration. 
 Conditional mouse models of pancreatic cancer have proven invaluable in 
discerning the biologic events of significance for this disease (reviewed in (175)).  Such 
events include the relevance of KRAS activation within different lineages of the pancreas 
that lead to pancreatic intraepithelial neoplasia formation, the combined effects of mutant 
KRAS and candidate tumor suppressor gene inactivation in PDA progression and 
metastasis (176), and the biological characteristics of this disease with relevance for 
clinical management (137; 145; 166; 167; 177; 178). However, notable efforts to 
represent the aggressive metastatic phenotype of pancreatic cancer have resulted in a 
paucity of models of the oligometastatic phenotype that are encountered in up to 10-20% 
of human pancreatic cancer patients (28; 179; 180). In the future, studies that incorporate 
information regarding metastatic burdens into both human outcome data and phenotypic 
analyses of conditional mouse models should generate additional insights into the biology 




Figures and Tables 
Figure 3-1: Histologic and Molecular Features of Human Oligometastatic 
Pancreatic Cancer 
 (A) Examples of primary tumor tissues collected at autopsy from patient A56 with 
oligometastatic pancreatic cancer, and of patient A93 with widely metastatic pancreatic cancer. 
See also Figure 2. (B) Quantification of the percent tubular growth pattern (well to moderate 
gland differentiation) per histologic review of one complete cross section per PDA. Frequency 
distributions were compared by Fisher Exact Test. (C) Representative E-cadherin and vimentin 
immunolabeling in oligometastatic and widely metastatic PDA. (D,E) Representative TGFβ1 (D) 
and TGFβR2 (E) expression in two oligometastatic and two widely metastatic PDA. Insets in the 
A70 and A56 TGFβ1 stained tissues illustrate rare positive labeling stromal or immune cells.  
Arrows in TGFβ1 labeled sections of A43 and A93 illustrate positive labeling peritumoral 





Figure 3-2: Histologic Features of Oligometastatic and Widely Metastatic 
Pancreatic Cancers 
 (A) Examples of primary tumor tissues collected at autopsy from patients A77 and A70 with 
oligometastatic pancreatic cancer.  The arrow in A70 illustrates a single cancer cell within the 
stroma, shown at higher power in the inset. (B) Examples of primary tumor tissues collected at 
autopsy from patients A17 and A132 with widely metastatic pancreatic cancer. (C) Movats 
pentachrome and α-smooth muscle actin staining representative oligometastatic and widely 
metastatic PDA. (D) Histomorphology of metastases to the lymph node and lung of patient A70 
whose primary PDA tissue is shown in (A). (E) Perineural invasion in representative 

















Figure 3-3: Generation and Characterization of KPTC Mice 
 (A) Recombination of the LSL-KrasG12D/+ and LSL-Trp53 R172H/+ alleles in the pancreata but not 
kidneys of KPC and KPTC mice.  Recombination of one conditional Tgfbr2 allele is seen in 
KPTC mice specifically. (B) Kaplan-Meier survival curves of KPTC, KPC, KTC, KC and control 
mouse cohorts.  KPTC mice have a significantly shortened median survival compared to both 
KPC (p<0.0001) and KTC mice (p=<0.0001).  Medians survivals were compared by pair-wise 
log-rank tests. (C) Gross findings in a representative moribund KPTC mouse with hemorrhagic 
ascites and jaundice. (D) Representative KPTC tumor showing infiltration into the adjacent 
stomach wall (arrows).  (E) Representative well to moderately differentiated PDA in KPTC 
mouse shown in C,D.  (F) Frequency of ADM and mPanIN grades 1-3 in pancreata of KPC and 
KPTC mice at 4, 8 and 12 weeks timepoints.  The frequency of high grade PanIN (mPanIN3) is 
significantly higher in KPTC mice at 12 weeks (Chi-squared test), a subset of which also had 





Figure 3-4: Genotyping of Primary KPTC and KPC PDA Cells 
Recombination of the LSL-KrasG12D/+ and LSL-Trp53 R172H/+ alleles in the pancreata but not kidneys of KPC and KPTC mice.  Recombination of 
one conditional Tgfbr2 allele was also demonstrated in KPTC mice specifically.  KPC7, KPC8, KPTC1 and KPTC4 are also shown in Figure 3.3.  
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Figure 3-5: Loss of Cell-Autonomous Tgfbr2 Leads to a Loss of Metastatic Traits in 
KPTC Tumors 
 (A) Representative histologic features of poorly-differentiated versus well-differentiated regions 
of the same PDA in KPTC22.  Smooth muscle actin (SMA) highlights the greater abundance of 
stroma in the well-differentiated component.  (B) Quantification of the percent tubular 
morphology of KPTC or KPC PDA based on histologic review of one complete cross section per 
PDA.  KPTC tumors show a significant shift towards a more differentiated (tubular) morphology 
compared to KPC tumors.  Frequency distributions were compared by Fisher Exact Test. (C-G) 
Heterogeneity for immunolabeling of TgfβR2 and Tgfβ1 in representative KPTC3 PDA.  At 
scanning power (C) regions of both positive and negative labeling can be seen. These regions are 
shown at higher power in D and E, illustrating TgfβR2 positive labeling corresponds to poorly 
differentiated morphology (D), whereas loss of TgfβR2 labeling is present in the well-
differentiated morphology of this same tumor (indicated by dashed outline, (E). The inset in E 
demonstrates membranous labeling for TgfβR2.  By contrast, no difference in labeling for Tgfβ1 
expression is seen among poor (F) and well-differentiated regions (G) of this same PDA.  (H-K) 
Heterogeneity for immunolabeling of Tgfβr2 and Tgfβ1 in representative KPC2 PDA.   Similar to 
KPTC3, there is heterogeneity in intensity of Tgfβr2 labeling among the poor (H) and well-
differentiated (indicated by dashed outlines, (I) regions of this PDA.  Tgfβ1 expression is seen 
among poor (J) and well-differentiated regions (K) of this same PDA, although there is focal loss 
in the well-differentiated region (arrow, K). (L-O) Representative fibronectin immunolabeling in 
KPTC3 (L,M) and KPC2 (N,O) PDA tissues. Dashed lines outline well-differentiated PDA in M 
and O respectively. (P) Immunofluorescence labeling for E-cadherin in representative KPC and 
KPTC primary cells treated with vehicle or TGFβ1.  DAPI was used as a counterstain to visualize 








Figure 3-6: Extrapancreatic Tumors in KPC and KPTC Mice 
(A) Gross example of spinal tumor in KPC mouse. (B) Low power histologic view of the tumor shown in A.  The spine (sp) is shown at the left of 
the image. (C) Higher power histologic view of tumor shown in A, demonstrating features of a high-grade neoplasm with mitotic figures (arrow). 











Figure 3-7: Molecular Features of KPTC PDAs 
(A) Genotyping for Kras, Trp53 and Tgfbr2 recombination events in co-existent well 
differentiated (W) and poorly differentiated (P) PDA in KPTC mice. (B) Immunolabeling for 
Trp53 in primary KPTC and KPC PDA tissues. (C,D) Western blots of Smad4 and p16 










Figure 3-8: Cell-Autonomous Tgfβ Signaling Mediates the Efficiency of Metastatic 
Colonization of the Lungs 
(A) Gross metastatic burdens at necropsy in KPC (n=22) and KPTC mice (n=34). Frequency 
distributions were compared by Chi-Square test. (B) Quantification of cell proliferation in 
primary KPC and KPTC cells.  Data shown represent the mean ± standard deviation of three 
independent experiments per cell line.  (C) Quantification of gross metastatic lung colonization at 
three weeks following tail vein injection of 1 x 105 primary KPC versus KPTC cells.  Data shown 
represent the mean ± standard deviation of at least four primary cell lines per genotype, with each 
line injected into at least four mice per experiment.  (D) Representative lungs in mice injected 
with KPC6 or KPC15 primary cells.  Mice were sacrificed three weeks after injection of 1 x 105 
primary cells. (E) Histologic and immunolabeling features of spontaneous lung metastases in 
representative KPC and KPTC mice.  Compared to the background normal lung, there is no 
difference in labeling for Tgfβr2 or Tgfβ1 in the metastatic PDA cells.  Scale bar, 100 μm.  
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Figure 3-9: Cell-Autonomous Tgfβ Signaling Mediates the Efficiency of Metastatic 
Colonization of the Liver 
(A) Example of intravascular PDA in KPTC mouse liver.  (B) Higher power of intravascular 
PDA illustrating intraluminal red blood cells and lymphocytes (arrow). (C) Higher power of 
intravascular PDA illustrating adjacent bile ducts (bd, arrows). (D) CD31 labeling of liver shown 
in A illustrating intravascular PDA involvement of the portal vein within a portal triad.  a, artery; 
v, vein; bd, bile duct; *, lumen of intravascular PDA.  (E) CK19 labeling of intravascular PDA.  
(F) p53 labeling of intravascular PDA.  (G,H) Representative intravascular metastases with more 
complex growth features and size.  (I) Representative invasive liver metastasis. Arrow indicates 
the reactive stromal response.  (J) Intravascular (itv) and invasive (inv) liver metastases in KPC 
mouse. (K) Frequency of intravascular versus invasive liver metastases in KPC and KPTC mice.  
Frequency distributions compared by Fisher Exact Test. (L) Fibronectin labeling in intravascular 







Figure 3-10: Tgfβ Signaling Promotes the Secretion of Novel Mediators of Distant 
Metastasis 
(A) Schematic of experimental approach for identifying TGFβ-stimulated differentially secreted 
proteins using iTRAQ. (B) Hierarchical cluster analysis of the 48 secreted proteins identified as 
more abundant in the KPC secretome. See also Table S4. (C) Western blots of total protein 
extracted from KPC and KPTC primary cell lines and labeled for Col6A1 and LCN2 protein. 
Levels of GAPDH are shown as a loading control. (D) Immunolabeling for Col6A1 and Lcn2 in 
representative spontaneous KPC lung metastases. (E) Western blots demonstrating efficiency of 
knockdown of Col6A1 or Lcn2 in KPC2 cells.  (F) Western blots demonstrating efficiency of 
knockdown of Col6A1 in KPC9 cells. (G,H) Quantification of lung colonization by KPC2 cells 
(G) or KPC9 cells (H) stably transfected with scrambled, Col6a1 or Lcn2 shRNAs.  Data shown 
are the mean ± S.D of at least four animals per condition.  Comparisons were made using a 
Student’s T Test. (I) Western blots demonstrating overexpression of Col6A1 or LCN2 in KPTC4 
cells.  (J) Quantification of lung colonization by KPTC4 cells stably transfected with an empty or 
Col6a1 or Lcn2 expressing vector.  Data shown are the mean ± S.D of at least four animals per 






Figure 3-11: mRNA Expression of Candidate TGF-Associated Secreted Proteins 
Quantitative PCR for expression of Col6A1, LCN2, SDF1r and VCAM1 genes whose protein 
products were identified as more abundant in the KPC secretome.  Data shown represent the 
mean ± standard deviation of three independent PCRs per primary cell line.  At least three cell 
lines per genotype were analyzed. 
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Figure 3-12: Integrated Model of TGFβ Signaling in Pancreatic Cancer 
(A,B)  Cell-autonomous TGFβ signaling in PDA exists varies across geographic sites within a 
single PDA (A) and across different PDAs (B).  Low levels correspond to favorable histologic 
features and high levels correspond to unfavorable histologic features, aggressive behavior and 
worse outcome in patients.  (C) TGFβ signaling in normal pancreatic epithelial cells maintains 
tissue homeostasis, and is suppressive during carcinogenesis.  However, in PDA this pathway 
converts to a potent trigger of aggressive behavior and efficient metastasis to distant sites, 
potentially as a result of TP53 and SMAD4 mutations that occur in advanced stage PanINs.  By 
contrast, PDAs that retain wild type TP53 and SMAD4 retain the suppressive properties of the 




Table 3.1: Clinicopathologic Features of Patients Studied 













Sites of Metastasis 
25 59M Caucasian Moderate N N I 23 0  
77 84F Caucasian Moderate Y Not seen III 3 0  
13 59M Caucasian Poor Y Not seen IV 7 <10 
 
Liver, Lung, Para-
aortic Lymph Nodes 





56 54M Caucasian Well Y Not seen III 4 <10 
 
Liver, Adrenal 






17 50F Caucasian Poor Y Y IV 5 >100 Liver, Lung, 
Peritoneum 
43 85F Caucasian Moderate to 
Poor 
Y Y IV 2 >100 Liver 
93 74M Caucasian Moderate to 
Poor 




124 74M Caucasian Moderate to 
Poor 
Not seen Y IV 3 >100 Peritoneum 
125 69F Caucasian Moderate to 
Poor 
Y Y IV 0.5 >100 Liver 
31 64F Hispanic Poor Y Y IV 2 11-100 Liver, Lung 
51 68M Caucasian Poor Not seen Y IV 5 11-100 Liver 
132 79M Caucasian Moderate to 
Poor 
Not seen Y IV 10 11-100 Liver, Lung 
57 64F Caucasian Moderate to 
Poor 
Not seen Y IV 3 >100 Liver 
 72 
Table 3.2: Immunohistochemical Analysis of Patients Studied 
Case TGFB1 Immunolabeling TGFBR2 Immunolabeling 
25 Not stained (tissues exhausted) Not stained (tissues exhausted) 
77 Negative (internal controls positive) Weak positive 
13 Negative (internal controls positive) Negative (internal controls positive) 
33 Negative (internal controls positive) ND (autolysis) 
56 Negative (internal controls positive) Weak positive 
70 Negative (internal controls positive Strong positive 
17 Positive Strong positive 
43 Strong Positive Strong positive 
93 Strong Positive Strong positive 
124 Positive Positive 
125 Negative (internal controls positive) Positive 
31 Positive Strong positive 
51 Negative (internal controls positive) Positive 
132 Positive Strong positive 
57 Positive Strong positive 
 
Solid black line separates oligometastatic patients (top; n = 6) from widely metastatic 



























Table 3.3: Metastatic Burden in KPC and KPTC Mice 
 
 
The table shows clinical and metastatic burden data for KPC (n = 22) and KPTC (n = 
34) mice. All mice were followed until moribund, at which time they were sacrificed 
and complete necropsies were performed.  Sites of metastases are indicated for each 
animal.
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Liver Mets Lung Mets Lymph 
Node Mets 
KPC10 KPC Female 293.5 0      
KPC15 KPC Female 270 0      
KPC16 KPC Female 198 0      
KPC20 KPC Male 128 0      
KPC4 KPC Male 214 0      
KPC5 KPC Male 100 0      
KPC11 KPC Male 207 2   Yes   
KPC14 KPC Female 230 2    Yes  
KPC19 KPC Female 211 2    Yes  
KPC7 KPC Female 252 5 Yes  Yes Yes  
KPC1 KPC Female 153 6 Yes  Yes   
KPC9 KPC Male 125 9 Yes  Yes  Yes 
KPC8 KPC Female 126 24 Yes   Yes Yes 
KPC6 KPC Male 205 >10 Yes  Yes Yes  
KPC12 KPC Female 262 Innumerable   Yes   
KPC13 KPC Female 223 Innumerable Yes  Yes Yes  
KPC2 KPC Male 178 Innumerable Yes  Yes Yes Yes 
KPC22 KPC Female 389 Innumerable  Yes Yes  Yes 
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KPC3 KPC Male 229 Innumerable Yes Yes Yes Yes Yes 
KPC17 KPC Male 144 >10    Yes  
KPC18 KPC Male 259 >10  Yes    
KPC23 KPC Female 287 0      
KPTC12 KPTC Male 131 0      
KPTC13 KPTC Female 122 0      
KPTC16 KPTC Female 92 0      
KPTC17 KPTC Female 92 0      
KPTC19 KPTC Male 123 0      
KPTC20 KPTC Female 145 0      
KPTC21 KPTC Male 111 0      
KPTC24 KPTC Female 173 0      
KPTC25 KPTC Male 87 0      
KPTC26 KPTC Male 158 0      
KPTC28 KPTC Male 144 0      
KPTC29 KPTC Male 158 0      
KPTC30 KPTC Male 135 0      
KPTC31 KPTC Male 112 0      
KPTC32 KPTC Male 169 0      
KPTC33 KPTC Female 275 0      
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KPTC34 KPTC Male 205 0      
KPTC35 KPTC Male 137 0      
KPTC4 KPTC Female 153 0      
KPTC22 KPTC Male 90 1   Yes   
KPTC2 KPTC Male 134 2   Yes   
KPTC7 KPTC Female 225 2   Yes Yes  
KPTC10 KPTC Female 131 3   Yes   
KPTC3 KPTC Male 143 10  Yes Yes Yes  
KPTC1 KPTC Male 99 57 Yes     
KPTC15 KPTC Female 164 >24   Yes Yes Yes 
KPTC11 KPTC Female 131 Innumerable  Yes Yes Yes  
KPTC14 KPTC Male 130 Innumerable   Yes Yes Yes 
KPTC18 KPTC Female 129 Innumerable Yes Yes Yes  Yes 
KPTC23 KPTC Male 118 Innumerable    Yes  
KPTC5 KPTC Male 145 Innumerable   Yes Yes Yes 
KPTC6 KPTC Male 155 Innumerable Yes Yes Yes Yes Yes 
KPTC8 KPTC Male 122 Innumerable   Yes Yes  




Table 3.4: Histopathology of Mouse Tumors 
The table shows pathology data for KPC (n = 22) and KPTC (n = 34) mice, including 
tumor histology, degree of tumor cell differentiation, and percentage of 
tubular/ductal morphology. All mice were followed until moribund, at which time 
they were sacrificed and complete necropsies were performed. The corresponding 























 ID  Genotype Histology Differentiation of PDA Quantitation of Tubular 
(Ductal) Morphology per 
complete cross section 
KPC10 KPC Sarcomatoid Undifferentiated Not included 
KPC15 KPC PDA Well 100% tubular 
KPC16 KPC PDA Moderate/Poor 20% tubular 
KPC20 KPC PDA and sarcoma  Focus of PDA too small to 
quantify 
KPC4 KPC PDA Poor 30% tubular 
KPC5 KPC PDA Poor 30% tubular 
KPC11 KPC PDA Poor 20% tubular 
KPC14 KPC PDA Poor 20% tubular 
KPC19 KPC PDA Moderate 95% tubular 
KPC7 KPC PDA Poor 50% tubular 
KPC1 KPC PDA Moderate/Poor 70% tubular 
KPC9 KPC PDA Poor 30% tubular 
KPC8 KPC PDA Moderate/Poor 10% tubular 
KPC6 KPC PDA (2 primaries) Moderate and Moderate 70% and 80% tubular 
KPC12 KPC PDA Moderate 90% tubular 
KPC13 KPC PDA Moderate/Poor 50% tubular 
KPC2 KPC PDA Poor 10% tubular 
KPC22 KPC PDA Moderate/Poor 50% tubular 
KPC3 KPC PDA Moderate/Poor 20% tubular 
KPC17 KPC PDA Moderate/Poor Focus of PDA too small to 
quantify 
KPC18 KPC PDA Moderate/Poor 50% tubular 
KPC23 KPC PDA Moderate/Poor 50% tubular 
KPTC12 KPTC PDA Moderate 100% ductal 
KPTC13 KPTC PDA Moderate 90% ductal 
KPTC16 KPTC PDA Poor 5% ductal 
KPTC17 KPTC PDA Poor 5% ductal 
KPTC19 KPTC PDA Moderate 90% ductal 
KPTC20 KPTC PDA Moderate/Poor 70% ductal 
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KPTC21 KPTC PDA Moderate/Poor 80% ductal 
KPTC24 KPTC PDA Moderate/Poor 95% ductal 
KPTC25 KPTC PDA Moderate/Poor 40% ductal 
KPTC26 KPTC PDA Moderate/Poor Focus of PDA too small to 
quantify 
KPTC28 KPTC PDA Moderate/Poor 50% ductal 
KPTC29 KPTC PDA Moderate/Poor 50% ductal 
KPTC30 KPTC PDA Moderate 90% ductal 
KPTC31 KPTC PDA Moderate N/A 
KPTC32 KPTC PDA Moderate/Poor 80% ductal 
KPTC33 KPTC PDA Moderate 95% ductal 
KPTC34 KPTC PDA Well/Moderate 95% ductal 
KPTC35 KPTC PDA Moderate/Poor 80% ductal 
KPTC4 KPTC PDA Moderate/Poor 70% ductal 
KPTC22 KPTC PDA Poor 20% ductal 
KPTC2 KPTC PDA Moderate 90% ductal 
KPTC7 KPTC PDA Moderate 90% ductal 
KPTC10 KPTC PDA (2 primaries) Moderate and Poor 95% and 70% ductal 
KPTC3 KPTC PDA Moderate/Poor 80% ductal 
KPTC1 KPTC PDA Moderate 90% ductal 
KPTC15 KPTC PDA Moderate/Poor 50% ductal 
KPTC11 KPTC PDA with minor 
sarcomatoid component 
Moderate 70% ductal 
KPTC14 KPTC PDA with minor 
sarcomatoid component 
Moderate 10% ductal 
KPTC18 KPTC PDA with minor 
sarcomatoid component 
Moderate 5% ductal 
KPTC23 KPTC PDA Moderate/Poor 60% ductal 
KPTC5 KPTC PDA Poor Autolyzed 
KPTC6 KPTC PDA Moderate/Poor 50% ductal 
KPTC8 KPTC PDA Moderate 80% ductal 
KPTC9 KPTC PDA Moderate/Poor 60% ductal 
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Table 3.5: Subset of Differentially Expressed Secreted Proteins in KPC and KPTC Cell Lines 
Protein Function Rank Diff t.stat p.val 
Vascular Cell Adhesion Protein 1 (VCAM1) Angiogenesis - 0.064444 - 4.397933 1.32E-05 
C-C Chemokine 7 (CXCR4/SDF1) Chemotactic Cytokine - 2.641026 - 9.754383 2.78E-14 
Collagen alpha-1(VI) chain (COL6A1) ECM - 1.419753 - 5.290294 4.85E-07 
Growth-regulated alpha protein (CXCL1) Chemotactic cytokine - 2.238095 - 5.057773 1.45E-05 
Galectin-3 binding protein (LGALS3bp) ECM/Binds Laminin - 0.654189 - 5.964684 3.47E-09 
Glucose-6-phosphate isomerase (GPI) Glycolysis   2.369048   16.08217 1.24E-41 
Superoxide dismutase (SOD1) Oxidative Stress   1.885965   12.89282 8.68E-32 
Annexin A3 (ANX3) Inflammation/Angiogenesis   1.614719   10.51269 6.92E-23 
Mucin-1 (MUC1) Intracellular 
Signaling/Apoptosis 
  1.952381   5.786547 1.93E-07 
Apoptosis regulator BAX Apoptosis 2.6   5.750236 6.32E-06 
 
The above list includes 10 of the 391 significantly differentially expressed proteins. Secretome data were converted to ranks so as to 
reduce the influence of such outliers.  The negative t-statistics indicate proteins that are expressed in KPC (top 5 proteins in this table), 
while the positive numbers indicate those that are more highly expressed in KPTC (bottom 5 proteins in this table).  The p-values 








Chapter 4 : Characterization of the Immune Response in PDA 
Tumors with Abrogated TGFβ Signaling
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Introduction 
Despite advances in our understanding of the events the give rise to and promote 
the progression of pancreatic adenocarcinoma (PDA), five-year survival rates for the 
disease remain abysmally low (119). Treatment options are limited, especially for the 
majority of patients that are diagnosed with metastatic disease (129; 181). One promising 
avenue of research is that of cancer immunotherapy. Harnessing the body’s own immune 
system to target and kill tumor cells addresses many of the pitfalls of current therapies, 
namely their lack of specificity and inability to maintain durable responses (106; 182). 
Significant challenges for the field exist, as tumor cells and the surrounding 
microenvironment employ a number of mechanisms that serve as barriers to proposed 
cancer immunotherapies. Analysis of immune cell subsets in tumor tissues has yielded 
important insights into many of these mechanisms, and has highlighted the role an 
immunosuppressive microenvironment plays in aiding tumor growth (75; 76). Improved 
survival has been noted in patients that develop robust lymphocyte responses in contrast 
to those whose predominant infiltrate is comprised of tumor-promoting, 
immunosuppressive cells (54; 89).  
In PDA, several groups have documented the inflammatory response at 
preinvasive and invasive stages in human tissues as well as within animal models of the 
disease (86; 183; 184). As has been noted in other tumor types, effector lymphocytes are 
vastly outnumbered by immunosuppressive cell subsets, including T regulatory cells, 
tumor-associated macrophages, and myeloid-derived suppressor cells (88; 185). 
Understanding how each of these immune cell populations is recruited into the tumor, 
 83 
and how they subsequently interact with tumor and stromal cells is critical if we are to 
overcome the barriers they impose on a productive immune response.  
TGFβ, a master regulatory cytokine, is known to be dysregulated in cancer. 
During early stages of cancer initiation, TGFβ acts to inhibit cell growth by facilitating 
cell cycle arrest and apoptosis. In later stages of tumor development and invasion, TGFβ 
exerts tumor-promoting effects including enhancement of cell migration and contributing 
to the suppressive microenvironment that induces immune tolerance (40; 186). TGFβ 
suppresses the activities of T cells that would otherwise mediate tumor rejection, and also 
coordinates the recruitment of myeloid cell populations (including neutrophils and 
monocytes) (67; 187). It is also essential for the differentiation of T regulatory cells, 
further inhibiting immune-mediated tumor cell killing (66).   
TGFβ signaling is perturbed in the majority of PDA patients (20). Loss of 
SMAD4 function has been described in greater than 50% of cases, with loss of 
expression correlating with widely metastatic disease and worse prognosis (28; 35; 66; 
120). A smaller subset of patients develop mutations in TGFβR2 (34),  and as discussed 
in the previous chapter, loss of TGFβR2 (as well as decreased TGFβ1 levels) correlate 
with oligometastatic disease. Given the immunomodulatory functions of the TGFβ 
pathway, we used transgenic mouse models of PDA to interrogate how immune cell 
populations change in the context of impaired signaling, and whether such alterations 
influence metastatic propensity of the primary tumor. 
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Materials and Methods 
Antibodies 
Primary antibodies raised against F4/80 (#123110), CD11c (#117309), Gr-1 (#108422), 
CD45 (#103114), Ly-6C (#128011), I-A/I-E (#107622), CD4 (#100443), CD8a 
(#100744), CD19 (#115511), NK-1.1 (#108728), and CD25 (#102007) were purchased 
from BioLegend; I-A/I-E (#11-5321-81) was purchased from eBioscience; CD16/CD32 
mouse Fc Block (#553142), CD11b (#561114), Ly-6G (#560599), CD11b (#562317), 




 mice (147), 129S4-Trp53tm2Tyj, B6.129S6-
Tgfbr2tm1Hlm and Ptf1a
tm1.1(cre)Cvw 
mice (150) (described in the previous chapter) were 
used in accordance with the Johns Hopkins Animal Care and Use Committee regulations. 
Each of the four strains of mice were backcrossed onto a C57BL/6 background in 4-6 
generations using marker assisted selection. Single nucleotide polymorphism genotyping 
was performed at the DartMouse™ Speed Congenic Core Facility at the Dartmouth 
Medical School. DartMouse uses the Illumina (San Diego, CA) GoldenGate genotyping 
assay to analyze 1449 SNPs spread throughout the genome.  Mice were determined to be 
>99% C57Bl/6 prior to cross-breeding to generate KPC and KPTC animals.  
Lymphocyte Isolation  
Resected pancreatic tumors were minced into 3-5 mm
2 
pieces and enzymatically digested 
with collagenase type IV and hyaluronidase for 1 hour at 37°C. Following digestion, cells 
were passed through a 70 μM nylon cell strainer (BD Biosciences) and washed in RPMI 
1640 media. Splenocytes were also harvested from tumor-bearing and control animals for 
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flow cytometric analysis. After harvest, spleens were crushed through 70 μM nylon cell 
strainers, washed in cold phosphate-buffered saline (PBS), and centrifuged at 1400rpm 
for 10 minutes at 4°C.  Cell suspensions were incubated in ACK lysis buffer (Quality 
Biological) to lyse red blood cells and washed in cold PBS. Cell pellets were resuspended 
in cold FACs buffer (HBSS, 1% FCS and 0.1% sodium azide) and counted by tryphan 
blue exclusion prior to staining. 
Flow Cytometry Staining 
For flow cytometric analysis, splenocytes and TILs (10
6
) were first incubated with Fc 
receptor block (BD Pharmingen) for 5 minutes at 4°C. Cells were incubated for 30 
minutes at 4°C with fluorochrome-conjugated antibodies in a volume of 0.1ml (Table 4.1 
includes antibody concentrations). For intracellular staining, the Cytofix/Cytoperm 
Fixation/Permeabilization staining kit (BD Pharmingen) was used. Briefly, cells were 
fixed for 30 minutes at 4°C, washed with FACs buffer, and permeabilized for 30 minutes 
at 37°C. After washing in FACs buffer, cells were incubated for 30 minutes at room 
temperature with fluorochrome-conjugated FoxP3 (Table 4.1) in a volume of 0.1ml. Cells 
were washed in FACs buffer before acquisition on a LSR-II Flow Cytometer or FACs 




Reduced TGFβ Signaling Alters the Immune Response to PDA in a Compound 
Mutant Mouse Model of PDA 
In the previous chapter, we described a novel genetically engineered mouse model 
of PDA with impaired TGFβ signaling. KPTC mice develop aggressive PDA, but 
ultimately succumb to oligometastatic disease. Secretome analysis of  KPTC and KPC 
cells highlighted differences in chemokine axes that regulate immune cell trafficking. To 
assess how these changes influenced the immune cell composition of tumors, we isolated 
tumor-infiltrating leukocytes from KPC and KPTC tumors and subjected them to 
fluorescence activated cell sorting analysis.  
The four mutant mouse strains used to create KPTC mice are a mix of C57Bl/6 
and 129 substrains. To alleviate concerns that strain differences may influence immune 
infiltrate profiles, each strain was backcrossed to the C57Bl/6 background prior to 
breeding KPC and KPTC mice. Doing so provided the added benefit that cell lines 
derived from these tumors could be used for future in vivo and in vitro experiments where 
immune responses are assessed or quantified. To confirm that backcrossing did not alter 
the phenotype of these animals, we monitored cohorts of mice for survival and metastatic 
burden. As was seen in mice on a mixed genetic background, loss of one allele of  
TGFβR2 abolished TGFβ-mediated growth inhibition in PDA.   KPTC mice (n = 39) had 
a median survival of 3.5 months with 100% mortality by 5.3 months (Figure 4.1A). This 







 mice, KPC, p = 0.0008). At necropsy, hemorrhagic ascites and obstructive, 
fibrotic pancreatic tumors were noted. As depicted in Figure 4.1B, KPTC frequently 
 87 
develop oligometastatic (<10 metastases) disease. When observed, metastases were found 
in the liver, lungs, and diaphragm of KPTC animals, modeling the spectrum of disease 
seen in PDA patients.    
Total leukocyte infiltrate was evaluated in a small subset of animals using the 
pan-leukocyte marker, CD45. Leukocyte infiltrate was slightly increased in KPTC mice 
compared to KPC, however, these differences were not statistically significant (Figure 
4.2).  Next, we evaluated whether particular immune populations infiltrate preferentially 
in KPTC tumors. Given that others have shown increased myeloid cell accumulation in 
response to aberrant TGFβ signaling (67; 68), we used two generalized myeloid cell 
markers (CD11b and Gr-1) to quantify myeloid infiltrate in KPC and KPTC tumors. 
Once again, increases in myeloid cells were seen in KPTC mice, but these differences did 
not quite reach statistical significance (Figure 4.3). Myeloid cells are a heterogeneous 
population of cells that include macrophages, neutrophils, immature monocytes, and 
myeloid-derived suppressor cells (MDSCs). MDSCs can be further classified into 
granulocytic and monocytic subsets based on cell surface marker expression and the 
pathways they use to mediate their suppressive functions (188). Notable increases in 
granulocytic MDSCs were seen in KPTC tumors (Figure 4.4A). Additionally, a slight 
elevation in monocytic MDSCs, and decreased macrophage infiltrate were observed 
(Figure 4.4B & C).   
TGFβ Signaling in Tumor Cells Contributes to an Immunosuppressive 
Microenvironment by Promoting T Regulatory Cell Accumulation 
Lymphoid cells make up a small percentage of the overall immune infiltrate in 
PDA tumors (184).  In our mutant mouse models of PDA, lymphocytes account for 5-8% 
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of the total leukocyte infiltrate (Figure 4.2 & 4.5). Analysis of T cell subsets showed no 
appreciable differences in the numbers of infiltrating CD4+ or CD8+ cells in KPTC 
tumors compared to KPC (Figure 4.5 A & B). Interestingly, we did see a small increase 
in CD19+ B cells in KPTC mouse tumors, shown in Figure 4.5C.  
Despite observing no quantitative changes in CD4+ T cell infiltrate in KPTC 
mice, we were interested to see whether reduced TGFβ signaling altered the polarization 
of these T cells. T regulatory cells are a subset of CD4+ T cells that are known to 
accumulate in early precursor lesions of PDA, acting as barriers towards an effective anti-
tumor immune response (66; 88).  As shown in Figure 4.6, in sharp contrast to KPC mice, 
nearly all the KPTC tumors lacked T regulatory cell infiltrate at the time they succumb to 
disease.  
Accumulation of Immune Aggregates in the Primary Tumors of KPTC Mice 
Quantitative analysis of tumor infiltrating cells provides useful information about 
the overall immune response; however, comprehensive analysis includes examination of 
how these immune cells are dispersed or localized within the tumor microenvironment. 
We have just begun to address this question, but interesting immune cell localization 
patterns have become apparent. Foci of immune cells clustered in aggregates have been 
noted in KPTC tumors (Figure 4.7A & B). In contrast, KPC tumors more frequently 
exhibit immune infiltrate dispersed throughout the tumor microenvironment (Figure 
4.7C). A more thorough examination of the composition of these immune aggregates as 
well as the localization of key immune cell subsets is ongoing.        
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Discussion 
Given that TGFβ is critical in the regulation of immune responses (69), and that 
this signaling pathway is often impaired in PDA (20), we questioned how a reduction in 
TGFβ signaling in the tumor epithelium may influence the immune response during PDA 
carcinogenesis. Using the conditional mouse model of PDA described in the previous 
chapter, we profiled key myeloid and lymphoid subsets of cells via fluorescence 
activating cell sorting.  
Notably, we observed a slight increase in overall immune infiltrate in KPTC 
mouse tumors compared to the tumors of KPC mice. Our sample sizes in these two 
cohorts are still small, so it is possible that a statistically significant increase in leukocyte 
infiltrate will be observed as we analyze more animals. Importantly, while the TGFβ 
signaling pathway is known to control genes that control immune cell trafficking, 
perturbing this pathway may have more appreciable effects on the types of immune cells 
that infiltrate tumors (81). Our data indicate that this might be the case, as we observed 
increases in some immune cell populations (granulocytic MDSCs and B cells) with 
concomitant decreases in others (macrophages and T regulatory cells). Additionally, our 
analysis to date has been carried out on moribund mice. Studies done in other mouse 
models indicate that there are temporal changes in immune cell infiltrate as tumors 
progress (86), and thus, we have also begun to analyze how immune infiltrate changes as 
precursor lesions develop and progress into PDA.  
As has been reported by others, we observed an increase in myeloid cell 
accumulation in tumors where one copy of TGFβR2 is inactivated (67). Tumor-
infiltrating myeloid cells are a heterogeneous mix of neutrophils, macrophages, and 
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MDSC populations. In our model, the increase in myeloid infiltrate looks to be 
attributable to an increase in granulocytic MDSCs. G-MDSCs are appreciated for their 
striking ability to impede T cell immune responses. Recently, Stromnes et al. reported 
that G-MDSCs are responsible for suppression of T cell effector functions, and when 
these cells are depleted from mice bearing PDA tumors,  T cell-mediated tumor cell 
killing activity is restored (189). Additionally, research suggests that G-MDSCs can 
contribute to tumor progression in other ways, as they secrete a variety of cytokines and 
chemokines (including TGFβ) that influence processes from angiogenesis to extracellular 
matrix remodeling (188).  
Lymphoid cells are rare in PDA tumors, and the overwhelming majority of 
infiltrating lymphoid cells are immunosuppressive T regulatory cells (88). In PDA, these 
cells were found to migrate into early precursor lesions and stay elevated throughout 
carcinogenesis (86). Like MDSCs, T regulatory cells represent a significant obstacle for a 
productive anti-tumor immune response. Interestingly, reduced TGFβ signaling in the 
tumor epithelium resulted in a decreased accumulation of T regulatory cells in our model 
of PDA. The mechanism behind this finding is still unclear. T regulatory cells need TGFβ 
for their polarization and homeostasis (66), and it is possible that reduced TGFβ signaling 
in tumor cells results in less ligand in the surrounding milieu. While we have not 
examined TGFβ levels in the backcrossed model of mice, we did not observe any 
differences in ligand expression in the KPTC tumors on a mixed background (Chapter 3, 
Figure 3.5). Moreover, given the numbers of myeloid cells present that are capable of 
secreting TGFβ into the tumor microenvironment, it is likely that reduced ligand 
expression is not the mechanism controlling T regulatory cell accumulation. 
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Alternatively, altered TGFβ signaling in tumor cells may allow for the expression of 
genes that influence CD4+ T cell polarization. In addition to T regulatory cells, CD4+ T 
cells can differentiate into Th1, Th2, or Th17 subsets with differentiation being controlled 
largely by the surrounding milieu (66). Given that we do not see changes in the total 
CD4+ T cell population, but do observe decreases in the T regulatory subset, it is likely 
that another population of CD4+ T cells has increased in KPTC mice. Further studies are 
planned to look at Th1, Th2 and Th17 T cell populations in these animals. We are also 
exploring differences in the cytokines known to mediate this polarization, including IFN-
γ, IL-4 and IL-6. Finally, it is also possible that reduced TGFβ signaling results in the 
expression of chemokines known to recruit T regulatory cells to tumors, namely CCL22 
and CCL2 (190). Studies to test this mechanism are also planned.      
Absolute numbers of immune infiltrate provide valuable information on the 
immune status of the tumor microenvironment. A high proportion of  immunosuppressive 
cells portends a worse prognosis and complicates the use of immunotherapies in patients 
(88). With this said, it is also recognized that the localization of immune cells within the 
tumor stromal network is as important as quantitative data of subset populations (191). 
Immune cells act locally, and the roles they undertake at the invasive fronts of tumors are 
likely quite different than the functions they exert within a hypoxic or necrotic region of 
the mass. Likewise, given tumor heterogeneity, the surrounding milieu that greatly 
influences immune cell function and survival is going to be distinct in different regions of 
the tumor. We have just begun to look at immune cell localization in the KPTC model of 
PDA; however, obvious differences in how leukocytes cluster were observed. Aggregates 
of what appear to be mostly lymphoid cells were seen in several of the KPTC tumors, but 
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their exact composition and function has yet to be determined. Interestingly, lymphoid 
aggregates were recently described as forming in patients who received a GM-CSF-
secreting PDAC vaccine.  Analysis of these aggregates revealed a predominant Th17 
lymphoid signature, and their presence was correlated to better vaccine responses (192). 
In addition to characterizing these clusters of cells in the KPTC tumor microenvironment, 
we have also begun to use immunohistochemistry to examine how T regulatory cells and 
MDSCs are distributed within the tumor. Aside from looking at factors such as 
localization to the periphery, within the stroma, at invasive fronts, or within these 
aggregates we are also exploring whether immune cells accumulate preferentially in areas 
of the tumor that are more well or poorly differentiated. As described in Chapter 3, 
regions of the tumor that were poorly differentiated had higher levels of TGFβ signaling 
whereas moderately to well differentiated regions displayed reduced pathway activity.  
The data presented in this chapter are preliminary, as we have only analyzed a 
small subset of animals; however, they are in agreement with previously published 
reports demonstrating a relationship between altered TGFβ signaling in the tumor and a 
restructuring of the immune microenvironment (67; 193).  The additional experiments 
described above should help to answer key questions pertaining to the mechanisms that 
drive the altered immune microenvironment in the context of reduced TGFβ signaling, 
and how localized immune niches affect processes such as invasion and metastasis.     
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Figures and Tables 
 
 
Figure 4-1: Generation and Characterization of Backcrossed KPTC Mice 
As described in the Materials and Methods, all four strains of mice were first backcrossed onto a 
C57Bl/6 background. Compound mutant mice were bred and followed until moribund. (A) 
Kaplan-Meier survival curves of KPTC and KPC mouse cohorts.  KPTC mice have a 
significantly shortened median survival compared to KPC mice (p=0.0008). Medians survival 
was compared by pair-wise log-rank tests. (B) Gross metastatic burdens at necropsy in KPC 





Figure 4-2: Leukocyte Infiltrate in KPTC Mice 
 
Compound mutant mice were allowed to progress until moribund (KPC: n = 7; KPTC: n 
= 13). At sacrifice, tumors were harvested, digested, and single-cell suspensions were 
subjected to fluorescence activated cell sorting analysis. Total leukocyte infiltrate was 
evaluated based on CD45+ expression. Absolute numbers of cells were normalized to 









Figure 4-3: Myeloid Cell Infiltrate in KPTC Tumors 
 
Compound mutant mice were allowed to progress until moribund (KPC: n = 7; KPTC: n 
= 13). At sacrifice, tumors were harvested, digested, and single-cell suspensions were 
subjected to fluorescence activated cell sorting analysis. Total myeloid infiltrate was 
evaluated based on CD45+ CD11b+ Gr-1+ expression. Absolute numbers of cells were 













Figure 4-4: Myeloid Subset Analysis of KPTC Tumors 
 
Compound mutant mice were allowed to progress until moribund (KPC: n = 7; KPTC: n 
= 13). At sacrifice, tumors were harvested, digested, and single-cell suspensions were 
subjected to fluorescence activated cell sorting analysis. (A) Granulocytic MDSC 




 and MHC II- (p = 





 and MHC II- (p = 0.21). (C) Macrophage infiltrate was characterized as 
being CD45+ CD11b+ F4/80+ MHC II+ (p = 0.27). Absolute numbers of cells were 
normalized to tumor weight and compared using a Student’s T Test. 
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Figure 4-5: Lymphoid Infiltrate in KPTC Tumors 
 
Compound mutant mice were allowed to progress until moribund (KPC: n = 7; KPTC: n 
= 13). At sacrifice, tumors were harvested, digested, and single-cell suspensions were 
subjected to fluorescence activated cell sorting analysis. (A) CD4+ T cells were CD45+ 
CD3+ CD4+ (p = 0.84) (B) CD8+ T cells were CD45+ CD3+ CD8+ (p = 0.65) (C) B 
cells were CD45+ CD3- CD19+ (p = 0.38) Absolute numbers of cells were normalized to 






























Figure 4-6: T Regulatory Cell Infiltrate in KPTC Tumors 
Compound mutant mice were allowed to progress until moribund (KPC: n = 7; KPTC: n 
= 13). At sacrifice, tumors were harvested, digested, and single-cell suspensions were 
subjected to fluorescence activated cell sorting analysis. T regulatory cells were 
characterized as being CD45+ CD4+ CD25+ FoxP3+. Absolute numbers of cells were 













Figure 4-7: Immune Aggregates in KPC and KPTC Mouse Tumors 
 
Examples of primary tumor tissues collected at necropsy from KPTC and KPC mice. (A) Low-
power image of  KPTC mouse tumor with clusters of immune aggregates marked with black 
arrows. (B) Example of second KPTC mouse with a focus of immune infiltrates localized to the 
periphery of the tumor. (C) Example of a KPC mouse primary tumor with diffuse immune 
infiltrate throughout the stroma.   
 102 
 103 
Table 4.1: Antibodies for Flow Cytometry Analysis 
Antibody Clone Company Concentration 
PE anti-mouse F4/80 BM8 BioLegend 0.2ug/10
6
 cells 
APC anti-mouse CD11c N418 BioLegend 0.1ug/10
6
 cells 
PerCP-Cy5.5 anti-mouse CD11b M1/70 BD Biosciences 0.05ug/10
6
 cells 
AF700 anti-mouse GR-1 RB6-865 BioLegend 0.25ug/10
6
 cells 
PE-Cy7 anti-mouse CD45 30F11 BioLegend 0.008ug/10
6
 cells 
FITC anti-mouse I-A/I-E M5/114.15.2 eBioscience 0.18ug/10
6
 cells 
PE-CF594 anti-mouse CD11b M1/70 BD Biosciences 0.005ug/10
6
 cells 
APC anti-mouse Ly-6G 1A8 BD Biosciences 0.1ug/10
6
 cells 
PerCP-Cy5.5 anti-mouse Ly-6C HK1.4 BioLegend 0.1ug/10
6
 cells 
AF700 anti-mouse I-A/I-E M5/114.15.2 BioLegend 0.18ug/10
6
 cells 
Brilliant Violet 421 anti-mouse CD4 GK1.5 BioLegend 0.07ug/10
6
 cells 
PerCP-Cy5.5 anti-mouse NK1.1 PK136 BioLegend 0.4ug/10
6
 cells 
PE anti-mouse CD3 145-2C11 BD Biosciences 0.4ug/10
6
 cells 
Brilliant Violet anti-mouse CD8a 53-6.7 BioLegend 0.07ug/10
6
 cells 
APC anti-mouse CD19 6D5 BioLegend 0.1ug/10
6
 cells 
PE anti-mouse CD25 PC61 BioLegend 0.1ug/10
6
 cells 







Table 4.2: Primer Sequences for Mouse Genotyping 
 
Primer Name 5’-3’ Sequence 
Kras G12D Forward AGCTAGCCACCATGGCTTGAGTAAGTCTGCA 
Kras G12D Reverse CCTTTACAAGCGCACGCAGACTGTAGA 
Tp53 R172H Forward AGCTAGCCACCATGGCTTGAGTAAGTCTGCA 
Tp53 R172H Reverse CTTGGAGACATAGCCACACTG 
Tgfbr2 Lox Forward TAAACAAGGTCCGGAGCCCA 
Tgfbr2 Lox Reverse ACTTCTGCAAGAGGTCCCCT 
Ptf1a Cre Forward ATAGGCTACCTGGCCATGCCC 
Ptf1a Cre Reverse CGGGCTGCAGGAATTCGTCG 
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Chapter 5 : SMAD4 Loss Alters the Immune 




Whole exome sequencing analysis of human pancreatic tumors has revealed a set 
of 12 core signaling pathways and processes that are perturbed in the majority of PDA 
patients (20).  One of these pathways, the TGFβ signaling pathway, is a known mediator 
of critical homeostatic cellular processes including cell survival, differentiation and 
proliferation (40). The most prevalent alteration observed in this pathway in PDA 
patients is inactivation of a critical transcription factor, SMAD4. Loss of SMAD4 
function, via homozygous deletion or intragenic mutation followed by loss of 
heterozygosity, occurs in greater than 55% of patients with PDA (24). Importantly, 
SMAD4 disruption has been correlated to widely metastatic disease and a worse 
prognosis (27; 28; 120). A small subset of PDA patients harbor inactivating mutations in 
TGFβ receptor 2 (TGFBR2). Interestingly, unlike what has been observed in SMAD4-
deficient tumors, loss of TGFBR2 is associated with a more favorable prognosis 
compared to those with SMAD4 loss (35).  This difference is likely attributable to the 
effects of SMAD4-independent signaling, which is retained in tumors that lose SMAD4, 
but lost in those with TGFBR2 inactivation.  
In addition to its pivotal role in maintaining cellular homeostatic activities, TGFβ 
signaling acts as a potent regulator of immune responses, with profound influence on 
proliferation, differentiation, migration and survival of immune cells (81; 194). Not 
surprisingly, tumors with mutations in TGFβ pathway components exhibit markedly 
increased and altered immune profiles that can contribute directly to tumor progression 
and metastasis. Lu et al. coupled Ras pathway activation with TGFBR2 loss in murine 
head and neck epithelia, which resulted in the formation of metastatic head and neck 
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squamous cell carcinoma (HNSCC). These tumors produced higher levels of TGFβ1, 
which contributed to overt changes in stromal architecture and noted increases in 
neutrophil and macrophage infiltration (195).  In a mammary carcinoma model with 
conditional deletion of TGFBR2, an immature myeloid cell population was found to 
infiltrate tumors, and in turn, contribute to metastasis by producing matrix 
metalloproteinases (MMPs) (67).  In studies where downstream components of the TGFβ 
signaling family (namely, SMAD4) were inactivated, similar microenvironmental 
changes were observed. Using a mouse model of invasive colorectal carcinoma where 
inactivation of APC was coupled with loss of SMAD4 in the intestinal epithelia, 
Kitamura et al. demonstrated an expansion of immature myeloid cells at the invasive 
front of tumors. These cells were shown to contribute to tumor invasion via production of 
MMPs (68).  Similarly, Bornstein et al. showed that deletion of SMAD4 in head and neck 
epithelia resulted in mice that developed HNSCC with increased leukocyte accumulation 
(193).    
In the previous chapter, we examined infiltrating immune population alterations 
in a transgenic mouse model of PDA where TGFβ signaling was abrogated through 
conditional inactivation of TGFBR2. Given the complex nature of this signaling pathway, 
with its canonical and SMAD4-independent arms, we sought to test whether similar 
immunophenotypic changes are observed in the context of SMAD4 loss. We used 
shRNA-mediated knockdown to generate SMAD4-deficient PDA tumor cells that were 
implanted into the pancreata of mice. The resultant tumors were assayed for infiltrating 
lymphocyte content. Additionally, we utilized adoptive transfer experiments to determine 
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whether immature myeloid cells derived from mice bearing SMAD4-deficent tumors 




Materials and Methods 
Antibodies 
Primary antibodies raised against F4/80 (#123110), CD11c (#117309), Gr-1 (#108422), 
CD45 (#103114), Ly-6C (#128011), I-A/I-E (#107622), CD4 (#100443), CD8a 
(#100744), CD19 (#115511), NK-1.1 (#108728), and CD25 (#102007) were purchased 
from BioLegend; I-A/I-E (#11-5321-81) was purchased from eBioscience; CD16/CD32 
mouse Fc Block (#553142), CD11b (#561114), Ly-6G (#560599), CD11b (#562317), 
CD3 (#553063) and FoxP3 (#560402) were purchased from BD Biosciences. For 
Western blotting experiments, a primary antibody against SMAD4 (#sc-7966) was 
purchased from Santa Cruz Biotechnology and a corresponding anti-mouse HRP 
secondary antibody (NA9314)) was purchased from GE Healthcare UK. 
Mouse Strains and Cell Lines 
KPC tumor-derived cell lines were a gift from David Tuveson (Cold Spring Harbor 
Laboratories, Cold Spring Harbor, NY). Cells were cultured in DMEM (GIBCO, 
Invitrogen Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine 
/L L-
glutamine at 37 
o
C and 5% CO2. For experimental metastasis and adoptive transfer 
assays, C57Bl/6 male mice aged 5-6 weeks were purchased from Jackson Laboratory 
(Bar Harbor, ME). Experiments involving animals were carried out in accordance with 
the Johns Hopkins Animal Care and Use Committee regulations.  
shRNA Stable Knockdown 
SMAD4 shRNAs (TG501287, Origen) were purchased from Origen. KPC cells were 
cultured in Dulbecco's modified medium containing 10%FBS. Plasmid DNA transfection 
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of cells was performed using Attractene reagent (Cat. No., 301005, Qiagen) per the 
manufacturer’s instructions. Forty-eight hours after transfection, cells were passaged into 
media containing puromycin (5ug/ml) and maintained in selective culture medium until 
colonies appeared. GFP positive cells were sorted on a FACs Aria (BD Bioscience) and 
plated in 96-well plates to obtain single cell clones. Clones were grown in DMEM media 
containing 10% FBS, and inhibition of gene expression by shRNA was assessed by 
Western blot and quantitative real-time PCR analysis. 
Western Blotting  
Cell lysates were prepared by suspending cell pellets in RIPA buffer (20 mM Tris, 0.1% 
SDS, 1% Triton X-100, 1% sodium deoxycholate, pH 7.4) supplemented with protease 
inhibitor cocktail tablets (Roche diagnostics GmbH, Mannheim, Germany). Equal 
amounts of proteins were separated on SDS-polyacrylamide gel and transferred onto 
PVDF membranes (DuPont NEN, Boston, MA). Each membrane was hybridized with 
primary antibody followed by horseradish peroxidase (HRP)-linked IgG and visualized 
by the enhanced chemiluminescence (ECL) system (Amersham). Expression of β-actin or 
GAPDH were used as internal controls. 
Quantitative Real-Time PCR 
Total RNA was extracted from tissue samples using RNeasy mini Kit (Cat. No., 74104; 
Qiagen). RNA was treated with DNase I (Invitrogen) to digest remnant genomic DNA. 
System (Invitrogen) according to the protocol recommended by the manufacturer. For 
quantitative PCR, one microgram of RNA per sample was reverse transcribed into cDNA 
using SuperScriptTMIII Platinum® Two-Step qRT-PCR Kit (Invitrogen) according to 
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the protocol recommended by the manufacturer. Real-time quantitative RT-PCR analysis 
was performed using an automated sequence detection instrument (7300 Real Time PCR 
System, Applied Biosystems, CA, USA) for the real-time monitoring of nucleic acid 
green dye fluorescence (SYBR®Green, Invitrogen Inc, CA, USA). Relative fold-changes 
of analyzed gene expression compared to the housekeeping gene β-actin were determined 
by calculation of the 2
ΔΔCt
.  All analyses were performed in triplicate at least 2 times.  
Primer sequences available in Table 5.2.  
Orthotopic Implantation Model 
KPC and KPC-SMAD4 knockdown cell cultures were dissociated into single cell 
suspensions, counted, resuspended in Matrigel (BD Biosciences) and injected into the 
pancreata of C57Bl/6 mice (5 x 10
5
 cells per mouse).  After three weeks the animals were 
euthanized, tumors and spleens were harvested for immune infiltrate analysis, and 
numbers of macroscopic metastases were counted.  
Lymphocyte Isolation and Flow Cytometry Staining 
Resected pancreatic tumors were minced into 3-5 mm
2 
pieces and enzymatically digested 
with collagenase type IV and hyaluronidase for 1 hour at 37°C. Following digestion, cells 
were passed through a 70 μM nylon cell strainer (BD Biosciences) and washed in RPMI 
1640 media. Splenocytes were also harvested from tumor-bearing and control animals for 
flow cytometric analysis. After harvest, spleens were crushed through 70 μM nylon cell 
strainers, washed in cold phosphate-buffered saline (PBS), and centrifuged at 1400rpm 
for 10 minutes at 4°C.  Cell suspensions were incubated in ACK lysis buffer (Quality 
Biological) to lyse red blood cells and washed in cold PBS. Cell pellets were resuspended 
in cold FACs buffer (HBSS, 1% FCS and 0.1% sodium azide) and counted by tryphan 
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blue exclusion prior to staining. For flow cytometric analysis, splenocytes and TILs (10
6
) 
were first incubated with Fc receptor block (BD Pharmingen) for 5 minutes at 4°C.  Cells 
were incubated for 30 minutes at 4°C with fluorochrome-conjugated antibodies in a 
volume of 0.1ml (Table 4.1 includes antibody concentrations). For intracellular staining, 
the Cytofix/Cytoperm Fixation/Permeabilization staining kit (BD Pharmingen) was used. 
Briefly, cells were fixed for 30 minutes at 4°C, washed with FACs buffer, and 
permeabilized for 30 minutes at 37°C. After washing in FACs buffer, cells were 
incubated for 30 minutes at room temperature with fluorochrome-conjugated FoxP3 
(Table 4.1) in a volume of 0.1ml. Cells were washed in FACs buffer before acquisition 
on a LSR-II Flow Cytometer or FACs Aria (BD Bioscience). 
Adoptive Transfer Assay 
C57Bl/6 mice were orthotopically implanted with either KPC or KPC-SMAD4 







 myeloid cells were sorted from the spleens of tumor-bearing mice using a FACs 
Aria (BD Biosciences). Myeloid cells were washed and mixed with either KPC or KPC-
SMAD4 knockdown cells at indicated ratios and implanted orthotopically into the 
pancreata of C57Bl/6 mice as described above. Myeloid cells sorted from the spleens of 
non-tumor bearing C57Bl/6 mice served as control cells in all experiments. After three 
weeks, animals were euthanized, spleens and tumors were harvested for immune infiltrate 




Loss of SMAD4 in KPC Tumor Cells Does Not Alter Metastatic Proficiency in an 
Orthotopic Model of PDA 
In the previous chapter, we used a genetically engineered mouse model of PDA 
with impaired TGFβR2 to assess how tumor immune infiltrate composition changed in 
response to deficiencies in TGFβ signaling. To determine the extent to which loss of 
SMAD-dependent TGFβ signaling contributes to changes in immune cell trafficking to 
PDA tumors, we generated SMAD4-deficient KPC tumor cells that were subsequently 
implanted into the mouse pancreas.  Stable knockdown of SMAD4 was confirmed at both 
the protein and mRNA level (Figure 5.1 A & B) prior to orthotopic implantation into 
mice.  Four weeks post-implantation, neither of the SMAD4-deficient clones 
demonstrated differences in tumor size compared to control KPC tumors (Figure 5.2A), 
suggesting that loss of SMAD4 did not alter tumor proliferation.   
Given that loss of SMAD4 is correlated to widely metastatic disease in human 
PDA patients (28), we next accessed metastatic burden in mice bearing SMAD4-deficient 
tumors (Figure 5.2B). Interestingly, four weeks post-implantation no differences in 
metastatic efficiency were observed in any of the SMAD4-deficient clones compared to 
control KPC tumors. A subset of mice implanted with SMAD4-deficient cells (KPC 
Clone #1) were followed for an additional two weeks to determine whether mice were 
succumbing to disease prior to the formation of metastases. As shown in Figure 5.3, a 
significantly greater number of metastases were found in mice bearing SMAD4 knockout 
KPC tumors six weeks post implantation. Frequent sites of metastases included the lungs, 
liver and diaphragm. While we would have liked to have carried out the remaining 
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experiments at this six-week time point, greater than 85% of the mice (irrespective of 
which cell line was used and the SMAD4 status of the tumor) died from their tumors 
within four weeks of injection.   
Leukocyte Infiltration is Increased in SMAD4-Deficient Tumors 
The TGFβ signaling pathway is known to be important in regulating leukocyte 
migration, differentiation and survival (54; 63). To determine whether SMAD4 loss 
augments the immune response in PDA, KPC (control) and SMAD4-deficient tumors 
were harvested four weeks after orthotopic implantation for immune infiltrate analysis 
via fluorescence activated cell sorting. The pan-leukocyte marker CD45 was used to 
quantify the total immune infiltrate in tumors. Leukocytes were increased in both 
SMAD4-deficient cell lines compared to their mock-transfected KPC controls (Figure 
5.4), with more robust differences being noted in KPC2. Because metastatic efficiency 
differences were observed at a later time point for KPC1 (Figure 5.3), we decided to look 
at leukocyte infiltrate in a small cohort of mice 6 weeks post-implantation with this cell 
line. As is shown in Figure 5.5, leukocyte infiltrate was not appreciably altered if KPC1 
SMAD4-deficient tumors were allowed to progress an additional two weeks.  
SMAD4 Loss in PDA Facilitates Granulocytic Myeloid Derived Suppressor Cell 
Recruitment into Tumors 
With an increase in total leukocyte infiltrate observed, we next examined how 
individual immune cell populations were altered in response to SMAD4 inactivation. To 
probe myeloid cell infiltration, we first looked at general myeloid markers: CD11b and 
Gr-1. An increase in total myeloid infiltration was observed in both SMAD4-deficient 
tumors; however, neither increase was found to be statistically significant (Figure 5.6A). 
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CD11b+ Gr-1+ myeloid cells are a heterogeneous population of cells that can include 
immature monocyte, macrophage, and granulocytic subsets. Additionally, these markers 
have been described as being expressed on a potent immunosuppressive set of cells 
known as myeloid-derived suppressor cells (MDSCs) (67). In both humans and mice, two 
separate subsets of these cells have been described. Mononuclear cell-like MDSCs (M-
MDSCs) histologically resemble immature precursors of macrophages while 
polymorphonuclear or granulocytic cell-like MDSCs (G-MDSCs) histologically resemble 
neutrophils (196). To address whether SMAD4 loss alters a particular myeloid subset of 
cells, we phenotyped the CD11b+ Gr-1+ myeloid cells isolated from the tumors of these 




, were found to be increased in 
SMAD4-deficient tumors (significantly increased in KPC2, Figure 5.6B; p = 0.008).  
Interestingly, M-MDSC infiltrate was found to be elevated in one SMAD4-deficient line 
(KPC1); however, decreases in the influx of these cells were observed in KPC2 SMAD4 
knockout tumors (Figure 5.6C).  
CD4+ T Cells are Recruited to KPC SMAD4-Deficient Tumors 
 MDSCs are characterized by their ability to produce anti-inflammatory cytokines 
such as TGFβ and IL-10 (67; 197). Additionally, PDA tumors are known to overexpress 
TGFβ ligand (38), and several groups have observed increased TGFβ ligand production 
in tumors with defective TGFβ signaling (118; 193).  Given the critical role that TGFβ 
plays in polarizing T cells, especially into T regulatory cells (66), we next examined T 
cell infiltrate in our KPC tumors with SMAD4 knockdown. As is illustrated in Figure 
5.7A, a significant increase in CD4+ T cells was observed in KPC2 SMAD4-deficient 
tumors compared to control KPC tumors (p = 0.04). Further analysis of these CD4+ T 
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cells revealed that T regulatory cells (defined here as CD4+ CD25+ FoxP3+ cells) were 
also increased in tumors with SMAD4 loss (Figure 5.7B).  
Adoptive Transfer of Myeloid Cells Does Not Alter Metastatic Propensity of KPC 
Tumors 
 Myeloid cells can contribute to many processes that are involved in tumor 
progression, including extracellular matrix remodeling, angiogenesis, and immune cell 
recruitment (198). It has been reported that macrophages and MSDCs promote metastasis 
via the secretion of matrix metalloproteinases (67; 68).  To test this in vivo, we sorted 
splenic-derived CD11b+ Gr-1+ myeloid cells from the mice bearing implanted KPC 
tumors, and adoptively transferred these cells with KPC tumor cells into the pancreata of 
mice. After three weeks, mice were sacrificed and macroscopic metastases were counted. 
As expected, primary tumor burden was not significantly altered when myeloid cells 
were implanted with tumor cells (Figure 5.8A).  Metastatic burden tended to increase 
with increasing myeloid cell concentrations, but this finding was not statistically 
significant (Figure 5.8B).     
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Discussion 
Perturbations to components of the TGFβ pathway in tumor cells can potentiate 
tumor growth via direct and indirect mechanisms (40). Ablation of TGFβ signaling in 
tumor cells dramatically alters the tumor microenvironment, which in turn, profoundly 
influences tumor cell proliferation and survival (69). As an example, studies have shown 
that impaired TGFβ signaling contributes to extracellular matrix deposition and 
remodeling, and these stromal cells act as sources of various growth factors and cytokines 
that fuel tumor cell proliferation (118).  
In addition to its well-known functions in controlling key cellular homeostatic 
mechanisms, the TGFβ signaling pathway is essential for regulating immune cell 
development, trafficking and function (69; 81). In animal models of head and neck, 
mammary, and colorectal carcinoma, inactivation of genes in this pathway in tumor cells 
alters the recruitment of immune cell populations to the tumor (67; 68; 193). In the 
previous chapter, we examined immune cell infiltrate in the context of TGFβR2 
inactivation. In this chapter, I present preliminary data showing that the immune 
microenvironment in PDA is altered in response to SMAD4 loss.    
 A conditional murine model of PDA with Kras activation coupled to SMAD4 loss 
resulted in papillary and mucinous precursor lesions that occasionally gave rise to 
adenocarcinoma (117). As we wanted to study the immune infiltrate in adenocarcinoma, 
we knocked out SMAD4 in KPC tumor cell lines and utilized an orthotopic implantation 
model to generate tumors for experimental analysis. Interestingly, only one of the 
SMAD4-deficient cell lines that we tested yielded an increase in metastatic burden 
compared to mock-transfected KPC tumor cells. One explanation for this observation is 
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that the parental KPC cell lines were derived from aggressive tumors harvested from 
moribund mice. Thus, these cells may already have acquired genetic or epigenetic 
changes that lend them to be more capable of metastasis, making SMAD4 loss redundant. 
As mentioned, even the parental (non-transfected) KPC cell lines kill the mice three to 
four weeks after implantation. The resultant tumor is large and obstructive, which may be 
killing the mouse before metastases become evident. Finally, it is also possible that 
screening additional clones might result in identifying SMAD4-deficient lines with 
increased metastatic propensity.  
 When analyzing the immune infiltrate, we observed an overall increase in 
leukocytes in SMAD4-deficient tumors. This is not particularly surprising given that 
TGFβ signaling regulates the transcription of genes that are necessary for leukocyte 
trafficking (199). Interestingly, the populations that were most altered in response to 
SMAD4 loss were regulatory immune cells (MDSCs and T regulatory cells). Others have 
demonstrated an increase in myeloid cell populations in murine tumor models with 
impaired TGFβ signaling (67; 68); however, their characterization of these cells has been 
limited to the general myeloid markers of CD11b and Gr-1. As mentioned, CD11b+ Gr-
1+ cells are a heterogeneous population of immune cells that include macrophages, 
immature monocytes, granulocytes and MDSCs. In our SMAD4-deficient model of PDA, 
the most significantly altered myeloid subset of cells were granulocytic MDSCs. G-
MDSCs are immunosuppressive cells that have also been implicated in promoting 
angiogenesis and invasion. Importantly, G-MDSCs are functionally and phenotypically 
distinct from M-MDSCs and macrophages (188; 200), which were not found to be altered 
in our SMAD4-deficient tumors. 
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 Myeloid cell populations, including MDSCs, are known to contribute to invasion 
namely through secretion of extracellular matrix remodeling enzymes (188). In our 
preliminary adoptive transfer experiments, we did not see increased metastasis when 
tumor cells were co-transplanted with myeloid cells obtained from tumor-bearing mice. 
One possible explanation for this observation is that we were using myeloid cells sorted 
from the spleens of tumor-bearing mice, as it was not feasible to sort enough cells 
directly from tumors. It is not clear whether myeloid cells derived from the spleen 
possess the same functional capabilities that tumor-derived myeloid cells do. Moreover, 
we used generalized myeloid markers (rather than specific markers for subsets such as G-
MDSCs) when sorting cells. This was also a feasibility issue, as obtaining enough cells 
for these adoptive transfer experiments is a limiting factor. Additional in vitro studies 
looking at matrix metalloproteinase secretion and/or co-culture invasion assays may help 
address the pitfalls of our in vivo approach.    
 We also observed a significant increase in CD4+ T cells in SMAD4-deficient 
tumors. CD4+ T cells differentiate into Th1, Th2, Th17, or T regulatory cells depending 
on the cytokine milieu. TGFβ ligand is necessary for polarization of both Th17 and T 
regulatory subsets (66). We did find an increase in T regulatory cells in our SMAD4-
deficient tumors; however, they only comprised about 8% of the total CD4+ infiltrate. 
While not specifically assayed for in our initial characterization of SMAD4-impaired 
tumors, there is some limited evidence that Th17 cells infiltrate PDA tumors (201). Their 
functional consequences in the tumor microenvironment are not yet understood. In 
addition to examining Th17 cells, we also plan to look at TGFβ levels in our SMAD4-
deficient tumors. PDA tumors are known to overexpress TGFβ ligand (38), but as 
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discussed in Chapter 3 (Table 3.2), oligometastatic PDA tumors lack TGFβ ligand 
expression.  Appreciable TGFβ ligand expression in SMAD4 knockout tumors could help 
to explain the influx of T regulatory cells that we have observed in these tumors.  
 In summary, although the data presented in this chapter are preliminary, they are 
in agreement with other studies examining immune infiltrate in SMAD4-deficient tumor 
models. An increase in leukocyte trafficking (especially of regulatory suppressive subsets 
of cells) in the context of SMAD4 loss indicates that SMAD-dependent signaling 
contributes to TGFβ-mediated immunosuppression. Future work to further characterize 
the immune infiltrate in these tumors in the form of additional subset analysis, TGFβ 
ligand expression, immune cell localization within tumors, and their functional roles in 
promoting invasion and metastasis, is necessary. Insight from these studies should help us 
better understand mechanisms of immune tolerance in the tumor microenvironment, and 
ultimately allow for better implementation of immunotherapy treatment regimens for 
PDA patients.  
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Figure 5-1: SMAD4 Protein and mRNA Expression Following Transfection of KPC 
Cell Lines with SMAD4 shRNAs. 
Two different KPC cell lines were transfected with shRNAs against SMAD4 using 
Attractene. After puromycin selection and GFP-sorting and plating, single-cell clones 
were grown to confluency. (A) Western blot of protein lysates from representative clones 
derived from both of the KPC cell lines showing near complete loss of SMAD4 protein 
expression. (B) Expression of SMAD4 was measured by qRT-PCR, normalized to ACTB 
and expressed as the fold change with respect to cells transfected with the control mock 
shRNA plasmid.  
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Figure 5-2: Characterization of SMAD4-Deficient KPC Tumor Cells 
Four weeks after implanting either SMAD-4 deficient or Mock KPC cells into the 
pancreata of mice (n=5 or 6 for each cohort), animals were sacrificed and assessed for 
tumor burden. (A) Average tumor size (mg) four weeks post injection. (B) Average 
number of metastases to all sites four weeks post injection. Comparisons were made 














Figure 5-3: Metastatic Burden in SMAD4-Deficient KPC Clone #1 Tumor Cells  
 
Four and six weeks after implanting either SMAD-4 deficient or Mock KPC Clone 1 cells 
into the pancreata of mice (n = 5 or 6 for each cohort), animals were sacrificed and 
assessed for tumor burden. Average number of metastases to all sites at four and six 









Figure 5-4: Leukocyte Infiltration in KPC vs. SMAD4-Deficient Tumors 
Tumor-infiltrating leukocytes were isolated from mice injected with either KPC (mock) 
or SMAD4-deficient KPC cells four weeks after implantation (n = 4 or 5 for each cohort), 
and analyzed via fluorescence activated cell sorting. Absolute numbers of cells were 








Figure 5-5: Leukocyte Infiltrate in SMAD4-Deficient KPC Clone #1 Tumor Cells 
 
Four and six weeks after implanting either SMAD-4 deficient or Mock KPC Clone 1 cells 
into the pancreata of mice (n = 4 for each cohort), animals were sacrificed and assessed 
for CD45+ leukocyte infiltrate. Absolute numbers of cells were normalized to tumor 
weight and compared using a Student’s T Test. 
 
 126 
Figure 5-6: Myeloid Infiltrate in KPC vs. SMAD4-Deficient Tumors 
Tumor-infiltrating immune cells were isolated from mice injected with either KPC 
(mock) or SMAD4-deficient KPC cells four weeks after implantation (n = 4 or 5 for each 
cohort), and analyzed via fluorescence activated cell sorting for myeloid markers. (A) 
Number of myeloid cells (defined as CD45+ CD11b+ Gr-1+) per milligram of tumor 
tissue. (B) Number of granulocytic myeloid derived suppressor cells (G-MDSCS) were 




positive. (C) Number of monocytic 





 positive. Absolute numbers of cells were normalized to tumor weight and 




Figure 5-7: CD4+ T Cell Infiltrate in KPC vs. SMAD4-Deficient Tumors 
Tumor-infiltrating immune cells were isolated from mice injected with either KPC (mock) or SMAD4-deficient KPC cells four weeks 
after implantation (n = 4 or 5 for each cohort), and analyzed via fluorescence activated cell sorting for myeloid markers. (A) Number 
of CD4+ T cells (defined as CD45+ CD3+) per milligram of tumor tissue (p = 0.04) (B) Number of T regulatory cells (Tregs) were 
defined as CD45+ CD25+ CD4+ and FoxP3+. Absolute numbers of cells were normalized to tumor weight and compared using a 




Figure 5-8: Characterization of KPC Tumors Following Adoptive Transfer of 
CD11b+ Gr-1+ MDSCs 
KPC tumor cells were implanted into the pancreata of mice. Three weeks later, spleens 
were harvested and CD11b+ Gr-1+ myeloid cells were sorted from splenocyte 
suspensions (donor cells). These myeloid cells were mixed with KPC tumor cells at the 
indicated ratios and injected into the pancreata of recipient mice (n=3-5 for each cohort). 
Tumors were allowed to grow for three weeks prior to harvesting for analysis. (A) Tumor 
sizes were compared for each of the indicated ratios of KPC:MDSCs. (B) Total number 
of macroscopic metastases were counted in each animal. Control mice received KPC 
tumor cells alone.  
 130 
Table 5.1: Primers Sets for Gene Expression Analysis 
 
Gene Product Size 5’-3’ Sequence 
ACTB – Forward 241bp GGCTGTATTCCCCTCCATCG 
ACTB – Reverse  CCAGTTGGTAACAATGCCATGT 
SMAD4 – Forward 124bp CAGCCATAGTGAAGGACTGTTGC 
SMAD4 – Reverse  CCTACTTCCAGTCCAGGTGGTA 
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Chapter 6 : Conclusions and Future Directions 
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The immune response in cancer is both dynamic and complex. There is compelling 
evidence to suggest that our immune system can recognize and eliminate nascent transformed 
cells, and yet during carcinogenesis, tumor cells are able to escape immune detection and 
proliferate. Similarly, we are beginning to elucidate the mechanisms by which chronic 
inflammation promote tumor initiation even as countless studies suggest that robust immune 
responses in patients are correlated with better outcomes (202).  
Central to understanding this paradox is an appreciation of the diversity and flexibility of 
the immune system. The innate and adaptive arms of the immune system are comprised of an 
array of immune cell subsets with unique and complementary roles designed to protect the host 
from pathogens, toxins, and neoplastic cells. Immune cells react to such threats by secreting 
cytokines and chemokines to mediate immune responses, releasing reactive oxygen and nitrogen 
species to thwart pathogens from multiplying, restructuring the local environment to protect 
against deleterious consequences of the mediators they release, and by engaging the adaptive arm 
to develop memory responses for future exposures (203). Unfortunately, tumor cells can utilize 
these same responses to facilitate their proliferative and metastatic capabilities.  As the function 
and survival of immune cells is a direct consequence of their localized environments, tumor cells 
can effectively hijack the immune response by shaping the surrounding milieu (126).   
The TGFβ signaling pathway has similar, paradoxical roles during carcinogenesis. This 
pathway is critical for preventing tumor formation by inhibiting cell division and promoting 
apoptosis. At later stages, TGFβ promotes tumor progression through a number of cell 
autonomous and cell non-autonomous mechanisms, including regulation of mitogenic factors 
that promote cell growth,  promoting extracellular matrix remodeling, and shaping the tumor 
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microenvironment to support immunosuppression and tolerance (40). The TGFβ signaling 
pathway is known to be mutated in the majority of PDA patients, with alterations most 
commonly observed in SMAD4 (24), and to a lesser extent in TGFβR2 (34).  This thesis focuses 
on understanding how cell autonomous and non-autonomous effects of the TGFβ signaling 
pathway promote PDA carcinogenesis and metastatic progression. Studies in this dissertation 
have contributed to understanding TGFβ-mediated PDA carcinogenesis and progression in the 
following ways: 
 
1) In Chapter 3, we showed that the different metastatic phenotypes of PDA are a result 
of the activation status of the TGFβ signaling pathway. During carcinogenesis, Tgfβ 
signaling works to restrain tumor cell proliferation; however, once invasive PDA 
develops, Tgfβ exerts its tumor-promoting effects. This switch is likely a 
consequence of acquired mutations that can bypass the effects of TGFβ-mediated 
growth inhibition (such as in p53). We showed that in contrast to widely metastatic 
disease, oligometastatic PDA is characterized by reduced expression of key TGFβ 
pathway components and favorable histologic features. We also described a novel 
murine model of oligometastatic PDA. This conditional mouse model with Tgfbr2 




 activation accelerated PDA 
carcinogenesis, but decreased metastatic efficiency.  
2) In Chapters 4 and 5, we highlighted preliminarily evidence to suggest that reduced 
Tgfβ signaling in tumor cells, via TgfβR2 or SMAD4 inactivation, results in changes 
to the immune profile in invasive PDA. Importantly, the most substantial differences 
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were noted in regulatory immune cell populations such as granulocytic MDSCs and T 
regulatory cells. Although not demonstrated by work done in this thesis, others have 
shown that these immune cells facilitate tumor progression by promoting immune 
tolerance.  
 
Additional experiments are underway to confirm that these subsets of immune cells are 
significantly altered in our murine model and human tissues of oligometastatic PDA. We have 
also begun to explore the localization of these immune cells within the tumor microenvironment, 
and the mechanisms by which they are recruited into pancreatic tumors.  
Going forward, our novel mouse model of oligometastatic PDA provides researchers with 
a tool to study the biology of the different metastatic phenotypes of PDA. Understanding the 
differences between and mechanisms that drive oligometastatic and widely metastatic disease, be 
they cell autonomous or indirect tumor microenvironmental influences, has the potential to 
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